Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MANISH R PATEL

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1457408254
CMS profile
66097
Location
SARASOTA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$4,671.42

152 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MANISH R PATEL

NPI 1457408254 · CMS profile ID 66097

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

SARASOTA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1457408254?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MANISH R PATEL, NPI 1457408254, CMS profile ID 66097. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457408254?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). MANISH R PATEL, NPI 1457408254, CMS profile ID 66097. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457408254?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
MANISH R PATEL, NPI 1457408254, CMS profile ID 66097, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1457408254?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

152 matching records · $4,671.42 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 152 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 152.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $11.1108/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738676605 CMS
Adaptive Biotechnologies Corporation $1,500.0008/27/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751727959 CMS
Pharmacyclics LLC, An AbbVie Company $14.2708/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725668619 CMS
Eisai Inc. $16.4608/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751227443 CMS
Jazz Pharmaceuticals Inc. $13.8808/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744457787 CMS
Puma Biotechnology, Inc. $11.9308/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750537335 CMS
E.R. Squibb & Sons, L.L.C. $13.0008/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727885481 CMS
BeiGene USA, Inc. $16.6808/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752949699 CMS
PFIZER INC. $13.3408/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743302547 CMS
Janssen Biotech, Inc. $13.7308/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719277447 CMS
Lilly USA, LLC $21.9408/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728543401 CMS
Celgene Corporation $12.6808/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727885539 CMS
Seagen Inc. $15.6508/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732461965 CMS
Daiichi Sankyo Inc. $11.3308/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739511151 CMS
E.R. Squibb & Sons, L.L.C. $24.1808/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727885483 CMS
Bayer HealthCare Pharmaceuticals Inc. $11.0208/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713647231 CMS
Amgen Inc. $14.3908/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741206073 CMS
PFIZER INC. $12.1407/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743271259 CMS
GENZYME CORPORATION $18.7207/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744252935 CMS
PFIZER INC. $24.7907/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743749273 CMS
Seagen Inc. $12.6807/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732461961 CMS
Merck Sharp & Dohme Corporation $15.9807/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747670251 CMS
ARRAY BIOPHARMA INC $12.2207/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743739525 CMS
Janssen Pharmaceuticals, Inc $17.5807/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719277437 CMS
AstraZeneca Pharmaceuticals LP $15.2407/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735808093 CMS
EMD Serono, Inc. $14.6607/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751281843 CMS
Janssen Biotech, Inc. $8.9107/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719277463 CMS
BeiGene USA, Inc. $14.6907/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752949701 CMS
Boehringer Ingelheim Pharma GmbH & Co.KG $562.6007/10/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749444153 CMS
Boehringer Ingelheim Pharma GmbH & Co.KG $258.2807/10/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749444161 CMS
Sun Pharmaceutical Industries Inc. $24.5407/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728286323 CMS
AstraZeneca Pharmaceuticals LP $15.7907/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735913301 CMS
AstraZeneca Pharmaceuticals LP $14.4307/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735826809 CMS
Janssen Biotech, Inc. $6.0407/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719277465 CMS
GENZYME CORPORATION $17.2207/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744252921 CMS
AstraZeneca Pharmaceuticals LP $7.7107/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736355937 CMS
DePuy Synthes Sales Inc. $36.4507/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718927191 CMS
Amgen Inc. $15.4106/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741414283 CMS
Jazz Pharmaceuticals Inc. $13.2306/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744466511 CMS
Genentech USA, Inc. $14.6406/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743052175 CMS
Bayer HealthCare Pharmaceuticals Inc. $17.8206/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713630593 CMS
Lexicon Pharmaceuticals, Inc. $12.8406/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751838377 CMS
Lilly USA, LLC $24.9706/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728533237 CMS
AstraZeneca Pharmaceuticals LP $13.8706/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735986183 CMS
Seagen Inc. $8.1006/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732461953 CMS
AstraZeneca Pharmaceuticals LP $14.8606/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736008881 CMS
Celgene Corporation $13.1606/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727885501 CMS
Celgene Corporation $13.1606/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753817223 CMS
Janssen Biotech, Inc. $11.3306/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719277445 CMS
GENZYME CORPORATION $16.4006/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744252917 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $19,664.39 177
PY2020 $4,671.42 152
PY2021 $23,135.78 152
PY2022 $16,177.19 171
PY2023 $14,693.90 187
PY2024 $22,332.09 176
PY2025 $22,002.76 183

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $7,769,064.14 2,999
PY2024 Principal investigator $3,591,049.61 1,017
PY2023 Principal investigator $1,986,878.44 417
PY2022 Principal investigator $2,985,902.81 298
PY2021 Recipient $7,607.59 4
PY2021 Principal investigator $3,326,767.53 362
PY2020 Recipient $2,584.53 4
PY2020 Principal investigator $4,078,821.62 985
PY2019 Recipient $5,673.76 1
PY2019 Principal investigator $5,858,177.05 1,184

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

2,999 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 BioNTech SE $40.00 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists
BNT326-01 No dispute reported 06/30/2026 1249018434
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $750.00 12/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer No dispute reported 06/30/2026 1233739075
Principal investigator 1 Daiichi Sankyo Inc. $5,000.00 12/30/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS9051-079 No dispute reported 06/30/2026 1223377601
Principal investigator 1 Daiichi Sankyo Inc. $28,000.00 12/30/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS9051-079 No dispute reported 06/30/2026 1223377603
Principal investigator 1 Janssen Research & Development, LLC $63,177.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175321670
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328966
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 12/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175323896
Principal investigator 1 Daiichi Sankyo Inc. $316.29 12/23/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377029
Principal investigator 1 Daiichi Sankyo Inc. $4,523.00 12/23/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377033
Principal investigator 1 Daiichi Sankyo Inc. $720.00 12/23/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377057
Principal investigator 1 Daiichi Sankyo Inc. $3,978.00 12/23/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377087
Principal investigator 1 Daiichi Sankyo Inc. $98.00 12/23/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377101
Principal investigator 1 Daiichi Sankyo Inc. $2,970.00 12/23/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377105
Principal investigator 1 Daiichi Sankyo Inc. $403.00 12/23/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377111
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 12/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175319046
Principal investigator 1 Janssen Research & Development, LLC $475.00 12/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175326948
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 12/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327935
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 12/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175329547
Principal investigator 1 Janssen Research & Development, LLC $2,555.00 12/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175329641
Principal investigator 1 ABBVIE INC. $2,333.00 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202531398
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 12/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380394
Principal investigator 1 Daiichi Sankyo Inc. $65.00 12/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380424
Principal investigator 1 Daiichi Sankyo Inc. $184.00 12/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380470
Principal investigator 1 Daiichi Sankyo Inc. $78.00 12/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380568
Principal investigator 1 Daiichi Sankyo Inc. $235.00 12/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380636
Principal investigator 1 Daiichi Sankyo Inc. $65.00 12/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380740
Principal investigator 1 Daiichi Sankyo Inc. $1,800.00 12/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380796
Principal investigator 1 Daiichi Sankyo Inc. $132.00 12/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380904
Principal investigator 1 Daiichi Sankyo Inc. $132.00 12/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380906
Principal investigator 1 Daiichi Sankyo Inc. $176.00 12/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380914
Principal investigator 1 Daiichi Sankyo Inc. $46.00 12/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380950
Principal investigator 1 Daiichi Sankyo Inc. $176.00 12/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381056
Principal investigator 1 Daiichi Sankyo Inc. $65.00 12/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381082
Principal investigator 1 Daiichi Sankyo Inc. $49.00 12/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381124
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 12/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381162
Principal investigator 1 Daiichi Sankyo Inc. $112.00 12/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381252
Principal investigator 1 Daiichi Sankyo Inc. $65.00 12/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381606
Principal investigator 1 Daiichi Sankyo Inc. $176.00 12/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381644
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327852
Principal investigator 1 Janssen Research & Development, LLC $64.00 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328104
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328571
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175329133
Principal investigator 1 Janssen Research & Development, LLC $199.00 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175329173
Principal investigator 1 Janssen Research & Development, LLC $64.00 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175329561
Principal investigator 1 SANOFI US SERVICES INC. $2,182.50 12/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1226082325
Principal investigator 1 Janssen Research & Development, LLC $64.00 12/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175326631
Principal investigator 1 Janssen Research & Development, LLC $64.00 12/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327263
Principal investigator 1 Janssen Research & Development, LLC $199.00 12/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327748
Principal investigator 1 Janssen Research & Development, LLC $64.00 12/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328014
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 12/17/2025 Non-covered Recipient Entity
University Of Minnesota Division Of Hematology Oncology And Transplantation
A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) No dispute reported 06/30/2026 1220634903
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 12/17/2025 Non-covered Recipient Entity
University Of Minnesota Division Of Hematology Oncology And Transplantation
A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) No dispute reported 06/30/2026 1220634905
Principal investigator 1 Boehringer Ingelheim International GmbH $11.20 12/17/2025 Non-covered Recipient Entity
University Of Minnesota Division Of Hematology Oncology And Transplantation
A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) No dispute reported 06/30/2026 1220634907
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $95.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220796895
Principal investigator 1 Daiichi Sankyo Inc. $3,457.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378317
Principal investigator 1 Daiichi Sankyo Inc. $1,299.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378323
Principal investigator 1 Daiichi Sankyo Inc. $138.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378371
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380262
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380274
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380282
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380284
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380286
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380288
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380290
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380292
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380294
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380302
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380314
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380316
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380318
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380320
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380326
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380328
Principal investigator 1 Daiichi Sankyo Inc. $2,709.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380346
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380350
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380352
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380358
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380360
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380366
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380368
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380376
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380382
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380390
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380392
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380398
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380406
Principal investigator 1 Daiichi Sankyo Inc. $1,800.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380410
Principal investigator 1 Daiichi Sankyo Inc. $112.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380412
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380418
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380436
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380438
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380440
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380442
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380448
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380452
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380454
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380460
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380462
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380464
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380466
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380478
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380482
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380484
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380486
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380500
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380504
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380506
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380514
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380522
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380524
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380526
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380528
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380530
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380534
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380536
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380540
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380542
Principal investigator 1 Daiichi Sankyo Inc. $65.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380552
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380556
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380562
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380564
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380566
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380572
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380578
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380580
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380582
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380584
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380608
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380620
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380622
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380632
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380640
Principal investigator 1 Daiichi Sankyo Inc. $4,340.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380650
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380654
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380656
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380664
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380668
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380674
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380676
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380678
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380696
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380698
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380700
Principal investigator 1 Daiichi Sankyo Inc. $176.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380702
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380704
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380706
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380710
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380712
Principal investigator 1 Daiichi Sankyo Inc. $5,040.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380726
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380730
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380732
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380734
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380736
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380744
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380750
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380762
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380764
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380780
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380782
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380786
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380788
Principal investigator 1 Daiichi Sankyo Inc. $3,229.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380794
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380798
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380804
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380808
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380812
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380816
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380824
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380832
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380838
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380844
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380846
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380850
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380854
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380856
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380862
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380864
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380866
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380870
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380872
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380874
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380876
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380878
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380882
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380884
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380886
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380888
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380900
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380908
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380910
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380916
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380928
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380930
Principal investigator 1 Daiichi Sankyo Inc. $176.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380932
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380934
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380938
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380948
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380952
Principal investigator 1 Daiichi Sankyo Inc. $65.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380962
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380966
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380968
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380982
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380986
Principal investigator 1 Daiichi Sankyo Inc. $2,709.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380992
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380994
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381004
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381006
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381008
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381016
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381018
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381020
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381024
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381030
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381032
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381034
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381040
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381046
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381050
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381058
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381066
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381070
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381072
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381076
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381080
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381090
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381098
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381100
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381102
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381104
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381108
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381110
Principal investigator 1 Daiichi Sankyo Inc. $184.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381118
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381126
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381132
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381134
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381138
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381140
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381142
Principal investigator 1 Daiichi Sankyo Inc. $3,229.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381146
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381150
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381158
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381160
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381164
Principal investigator 1 Daiichi Sankyo Inc. $2,709.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381166
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381168
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381182
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381190
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381194
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381198
Principal investigator 1 Daiichi Sankyo Inc. $65.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381204
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381208
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381210
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381212
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381214
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381218
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381226
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381234
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381238
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381248
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381256
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381258
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381264
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381266
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381272
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381282
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381284
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381286
Principal investigator 1 Daiichi Sankyo Inc. $65.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381290
Principal investigator 1 Daiichi Sankyo Inc. $176.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381292
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381294
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381304
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381306
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381308
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381316
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381324
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381326
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381328
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381330
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381332
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381338
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381340
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381352
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381356
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381364
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381368
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381376
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381378
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381380
Principal investigator 1 Daiichi Sankyo Inc. $450.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381386
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381388
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381398
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381408
Principal investigator 1 Daiichi Sankyo Inc. $3,229.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381410
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381412
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381422
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381426
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381428
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381434
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381442
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381444
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381450
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381452
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381454
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381460
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381462
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381464
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381468
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381474
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381480
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381482
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381484
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381488
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381490
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381496
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381498
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381500
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381504
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381506
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381516
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381518
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381520
Principal investigator 1 Daiichi Sankyo Inc. $140.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381524
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381526
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381530
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381538
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381540
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381542
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381544
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381546
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381550
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381556
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381560
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381562
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381564
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381580
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381586
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381596
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381604
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381610
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381620
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381622
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381628
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381630
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381632
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381634
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381636
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381638
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381648
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381654
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381656
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381666
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381670
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381672
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381674
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381678
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381688
Principal investigator 1 Daiichi Sankyo Inc. $132.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381690
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381698
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381702
Principal investigator 1 SANOFI US SERVICES INC. $125,410.30 12/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies No dispute reported 06/30/2026 1226081943
Principal investigator 1 Janssen Research & Development, LLC $3,803.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175327327
Principal investigator 1 Janssen Research & Development, LLC $64.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327546
Principal investigator 1 Janssen Research & Development, LLC $48,709.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175327807
Principal investigator 1 Janssen Research & Development, LLC $199.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327830
Principal investigator 1 Janssen Research & Development, LLC $2,555.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328180
Principal investigator 1 Janssen Research & Development, LLC $64.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328202
Principal investigator 1 Janssen Research & Development, LLC $199.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328370
Principal investigator 1 Janssen Research & Development, LLC $64.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328586
Principal investigator 1 Janssen Research & Development, LLC $2,596.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175328762
Principal investigator 1 Janssen Research & Development, LLC $64.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175329364
Principal investigator 1 Janssen Research & Development, LLC $2,265.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175329482
Principal investigator 1 Janssen Research & Development, LLC $3,803.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175329526
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 12/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175320548
Principal investigator 1 Janssen Research & Development, LLC $5,400.00 12/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175321168
Principal investigator 1 Janssen Research & Development, LLC $5,400.00 12/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175321525
Principal investigator 1 Janssen Research & Development, LLC $64,104.75 12/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 study of JNJ-95437446 in participants with advanced-stage solid tumors No dispute reported 06/30/2026 1175326722
Principal investigator 1 Incyte Corporation $2,502.00 12/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586729
Principal investigator 1 Incyte Corporation $2,502.00 12/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586733
Principal investigator 1 Incyte Corporation $2,502.00 12/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586738
Principal investigator 1 Incyte Corporation $3,625.00 12/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586796
Principal investigator 1 Incyte Corporation $3,625.00 12/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586799
Principal investigator 1 Incyte Corporation $4,433.00 12/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586904
Principal investigator 1 Incyte Corporation $4,433.00 12/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586908
Principal investigator 1 Incyte Corporation $4,805.00 12/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586933
Principal investigator 1 SANOFI US SERVICES INC. $125.00 12/10/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1226081860
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 12/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175320949
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 12/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175323206
Principal investigator 1 SANOFI US SERVICES INC. $3,629.25 12/05/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1226081795
Principal investigator 1 Daiichi Sankyo Inc. $6,538.00 12/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377025
Principal investigator 1 Daiichi Sankyo Inc. $5,166.00 12/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377041
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 12/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378347
Principal investigator 1 Daiichi Sankyo Inc. $112.00 12/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380356
Principal investigator 1 Daiichi Sankyo Inc. $176.00 12/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380806
Principal investigator 1 Daiichi Sankyo Inc. $46.00 12/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380990
Principal investigator 1 Daiichi Sankyo Inc. $65.00 12/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381228
Principal investigator 1 Daiichi Sankyo Inc. $46.00 12/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381612
Principal investigator 1 Daiichi Sankyo Inc. $143.00 12/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381668
Principal investigator 1 Incyte Corporation $2,850.00 12/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586930
Principal investigator 1 SANOFI US SERVICES INC. $75.00 12/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1226081864
Principal investigator 1 SANOFI US SERVICES INC. $2,335.50 12/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1226082034
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
University Of Minnesota Division Of Hematology Oncology And Transplantation
A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) No dispute reported 06/30/2026 1220634901
Principal investigator 1 Daiichi Sankyo Inc. $13.53 12/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368415
Principal investigator 1 Daiichi Sankyo Inc. $91.22 12/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368421
Principal investigator 1 Daiichi Sankyo Inc. $15.50 12/01/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377331
Principal investigator 1 Daiichi Sankyo Inc. $15.50 12/01/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377335
Principal investigator 1 Daiichi Sankyo Inc. $50.15 12/01/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377339
Principal investigator 1 Daiichi Sankyo Inc. $15.50 12/01/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377341
Principal investigator 1 Daiichi Sankyo Inc. $15.50 12/01/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377343
Principal investigator 1 Daiichi Sankyo Inc. $51.55 12/01/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377347
Principal investigator 1 Daiichi Sankyo Inc. $15.50 12/01/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377349
Principal investigator 1 Daiichi Sankyo Inc. $37.35 12/01/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377357
Principal investigator 1 Daiichi Sankyo Inc. $15.50 12/01/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377387
Principal investigator 1 Daiichi Sankyo Inc. $83.40 12/01/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377391
Principal investigator 1 Daiichi Sankyo Inc. $15.50 12/01/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377407
Principal investigator 1 Daiichi Sankyo Inc. $15.50 12/01/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377411
Principal investigator 1 Daiichi Sankyo Inc. $15.50 12/01/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377421
Principal investigator 1 Daiichi Sankyo Inc. $37.35 12/01/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377423
Principal investigator 1 Daiichi Sankyo Inc. $20.85 12/01/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377433
Principal investigator 1 Daiichi Sankyo Inc. $20.85 12/01/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377435
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380428
Principal investigator 1 Daiichi Sankyo Inc. $46.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380444
Principal investigator 1 Daiichi Sankyo Inc. $132.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380480
Principal investigator 1 Daiichi Sankyo Inc. $235.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380510
Principal investigator 1 Daiichi Sankyo Inc. $143.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380586
Principal investigator 1 Daiichi Sankyo Inc. $112.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380590
Principal investigator 1 Daiichi Sankyo Inc. $132.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380600
Principal investigator 1 Daiichi Sankyo Inc. $176.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380618
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380646
Principal investigator 1 Daiichi Sankyo Inc. $176.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380648
Principal investigator 1 Daiichi Sankyo Inc. $235.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380672
Principal investigator 1 Daiichi Sankyo Inc. $45.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380680
Principal investigator 1 Daiichi Sankyo Inc. $132.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380690
Principal investigator 1 Daiichi Sankyo Inc. $132.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380742
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380774
Principal investigator 1 Daiichi Sankyo Inc. $140.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380842
Principal investigator 1 Daiichi Sankyo Inc. $450.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380868
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380902
Principal investigator 1 Daiichi Sankyo Inc. $140.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380946
Principal investigator 1 Daiichi Sankyo Inc. $143.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380972
Principal investigator 1 Daiichi Sankyo Inc. $132.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380980
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380996
Principal investigator 1 Daiichi Sankyo Inc. $4,601.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381044
Principal investigator 1 Daiichi Sankyo Inc. $132.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381068
Principal investigator 1 Daiichi Sankyo Inc. $176.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381130
Principal investigator 1 Daiichi Sankyo Inc. $132.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381152
Principal investigator 1 Daiichi Sankyo Inc. $235.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381202
Principal investigator 1 Daiichi Sankyo Inc. $235.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381240
Principal investigator 1 Daiichi Sankyo Inc. $132.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381242
Principal investigator 1 Daiichi Sankyo Inc. $143.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381354
Principal investigator 1 Daiichi Sankyo Inc. $143.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381390
Principal investigator 1 Daiichi Sankyo Inc. $112.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381494
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381510
Principal investigator 1 Daiichi Sankyo Inc. $140.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381554
Principal investigator 1 Daiichi Sankyo Inc. $143.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381600
Principal investigator 1 Daiichi Sankyo Inc. $112.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381626
Principal investigator 1 Daiichi Sankyo Inc. $112.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381650
Principal investigator 1 Daiichi Sankyo Inc. $112.00 12/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381696
Principal investigator 1 Janssen Research & Development, LLC $15,687.50 12/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175326647
Principal investigator 1 Janssen Research & Development, LLC $18,298.80 12/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328028
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,690.00 11/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer No dispute reported 06/30/2026 1233739071
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $750.00 11/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer No dispute reported 06/30/2026 1233739073
Principal investigator 1 Incyte Corporation $594.00 11/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586828
Principal investigator 1 Incyte Corporation $331.00 11/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586843
Principal investigator 1 Incyte Corporation $325.00 11/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586881
Principal investigator 1 Incyte Corporation $379.00 11/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240587038
Principal investigator 1 Incyte Corporation $203.00 11/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240587046
Principal investigator 1 Incyte Corporation $203.00 11/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240587048
Principal investigator 1 Incyte Corporation $85.00 11/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240587088
Principal investigator 1 PFIZER INC. $300.00 11/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228727821
Principal investigator 1 Daiichi Sankyo Inc. $450.00 11/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381336
Principal investigator 1 Incyte Corporation $1,038.52 11/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586717
Principal investigator 1 Janssen Research & Development, LLC $3,803.00 11/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175327975
Principal investigator 1 Janssen Research & Development, LLC $2,596.00 11/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175328610
Principal investigator 1 Janssen Research & Development, LLC $3,300.00 11/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175328829
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380296
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380306
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380374
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380434
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380456
Principal investigator 1 Daiichi Sankyo Inc. $4,601.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380488
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380512
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380546
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380574
Principal investigator 1 Daiichi Sankyo Inc. $140.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380610
Principal investigator 1 Daiichi Sankyo Inc. $46.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380634
Principal investigator 1 Daiichi Sankyo Inc. $140.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380638
Principal investigator 1 Daiichi Sankyo Inc. $143.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380686
Principal investigator 1 Daiichi Sankyo Inc. $132.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380708
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380720
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380724
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380830
Principal investigator 1 Daiichi Sankyo Inc. $132.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380834
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380880
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380912
Principal investigator 1 Daiichi Sankyo Inc. $2,101.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380920
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380922
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380956
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380960
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380964
Principal investigator 1 Daiichi Sankyo Inc. $235.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380984
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381000
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381026
Principal investigator 1 Daiichi Sankyo Inc. $165.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381042
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381054
Principal investigator 1 Daiichi Sankyo Inc. $140.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381062
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381084
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381086
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381096
Principal investigator 1 Daiichi Sankyo Inc. $143.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381106
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381116
Principal investigator 1 Daiichi Sankyo Inc. $157.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381128
Principal investigator 1 Daiichi Sankyo Inc. $49.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381148
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381170
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381178
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381230
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381270
Principal investigator 1 Daiichi Sankyo Inc. $184.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381314
Principal investigator 1 Daiichi Sankyo Inc. $132.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381342
Principal investigator 1 Daiichi Sankyo Inc. $235.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381362
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381372
Principal investigator 1 Daiichi Sankyo Inc. $140.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381384
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381414
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381420
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381432
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381446
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381502
Principal investigator 1 Daiichi Sankyo Inc. $2,101.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381522
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381528
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381536
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381566
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381574
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381576
Principal investigator 1 Daiichi Sankyo Inc. $450.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381680
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381682
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381684
Principal investigator 1 Incyte Corporation $89.00 11/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586802
Principal investigator 1 Incyte Corporation $85.00 11/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240587080
Principal investigator 1 Incyte Corporation $85.00 11/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240587083
Principal investigator 1 Incyte Corporation $371.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586806
Principal investigator 1 Incyte Corporation $115.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586810
Principal investigator 1 Incyte Corporation $379.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586877
Principal investigator 1 Incyte Corporation $594.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586995
Principal investigator 1 Incyte Corporation $1,000.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240587041
Principal investigator 1 Janssen Research & Development, LLC $2,265.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175326672
Principal investigator 1 Janssen Research & Development, LLC $54.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175326800
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175326864
Principal investigator 1 Janssen Research & Development, LLC $699.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175327279
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175327780
Principal investigator 1 Janssen Research & Development, LLC $410.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175327927
Principal investigator 1 Janssen Research & Development, LLC $193.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175328414
Principal investigator 1 Janssen Research & Development, LLC $3,803.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175328845
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175329071
Principal investigator 1 Janssen Research & Development, LLC $410.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175329416
Principal investigator 1 Janssen Research & Development, LLC $89.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175329534
Principal investigator 1 Janssen Research & Development, LLC $171.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175329648
Principal investigator 1 Daiichi Sankyo Inc. $135.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377027
Principal investigator 1 Daiichi Sankyo Inc. $121.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377031
Principal investigator 1 Daiichi Sankyo Inc. $360.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377035
Principal investigator 1 Daiichi Sankyo Inc. $196.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377037
Principal investigator 1 Daiichi Sankyo Inc. $77.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377043
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377045
Principal investigator 1 Daiichi Sankyo Inc. $601.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377047
Principal investigator 1 Daiichi Sankyo Inc. $126.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377049
Principal investigator 1 Daiichi Sankyo Inc. $48.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377051
Principal investigator 1 Daiichi Sankyo Inc. $105.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377053
Principal investigator 1 Daiichi Sankyo Inc. $88.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377055
Principal investigator 1 Daiichi Sankyo Inc. $403.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377059
Principal investigator 1 Daiichi Sankyo Inc. $56.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377061
Principal investigator 1 Daiichi Sankyo Inc. $56.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377065
Principal investigator 1 Daiichi Sankyo Inc. $274.28 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377067
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377071
Principal investigator 1 Daiichi Sankyo Inc. $64.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377075
Principal investigator 1 Daiichi Sankyo Inc. $4,446.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377077
Principal investigator 1 Daiichi Sankyo Inc. $1,720.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377079
Principal investigator 1 Daiichi Sankyo Inc. $163.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377083
Principal investigator 1 Daiichi Sankyo Inc. $4,400.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377085
Principal investigator 1 Daiichi Sankyo Inc. $138.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377089
Principal investigator 1 Daiichi Sankyo Inc. $70.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377091
Principal investigator 1 Daiichi Sankyo Inc. $85.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377093
Principal investigator 1 Daiichi Sankyo Inc. $698.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377095
Principal investigator 1 Daiichi Sankyo Inc. $3,978.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377097
Principal investigator 1 Daiichi Sankyo Inc. $60.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377103
Principal investigator 1 Daiichi Sankyo Inc. $42.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377107
Principal investigator 1 Daiichi Sankyo Inc. $168.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377113
Principal investigator 1 Daiichi Sankyo Inc. $386.00 11/19/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377115
Principal investigator 1 Daiichi Sankyo Inc. $138.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378287
Principal investigator 1 Daiichi Sankyo Inc. $138.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378289
Principal investigator 1 Daiichi Sankyo Inc. $3,457.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378291
Principal investigator 1 Daiichi Sankyo Inc. $138.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378293
Principal investigator 1 Daiichi Sankyo Inc. $138.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378303
Principal investigator 1 Daiichi Sankyo Inc. $138.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378315
Principal investigator 1 Daiichi Sankyo Inc. $1,775.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378319
Principal investigator 1 Daiichi Sankyo Inc. $138.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378325
Principal investigator 1 Daiichi Sankyo Inc. $138.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378329
Principal investigator 1 Daiichi Sankyo Inc. $3,457.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378341
Principal investigator 1 Daiichi Sankyo Inc. $138.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378349
Principal investigator 1 Daiichi Sankyo Inc. $138.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378353
Principal investigator 1 Daiichi Sankyo Inc. $138.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378359
Principal investigator 1 Daiichi Sankyo Inc. $138.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378369
Principal investigator 1 Daiichi Sankyo Inc. $138.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378373
Principal investigator 1 Daiichi Sankyo Inc. $138.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378375
Principal investigator 1 Daiichi Sankyo Inc. $138.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378377
Principal investigator 1 Daiichi Sankyo Inc. $138.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378383
Principal investigator 1 Daiichi Sankyo Inc. $500.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380270
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380272
Principal investigator 1 Daiichi Sankyo Inc. $3,760.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380300
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380404
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380498
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380502
Principal investigator 1 Daiichi Sankyo Inc. $5,040.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380532
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380544
Principal investigator 1 Daiichi Sankyo Inc. $4,340.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380596
Principal investigator 1 Daiichi Sankyo Inc. $3,229.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380670
Principal investigator 1 Daiichi Sankyo Inc. $3,760.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380792
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380800
Principal investigator 1 Daiichi Sankyo Inc. $500.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380970
Principal investigator 1 Daiichi Sankyo Inc. $3,760.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380976
Principal investigator 1 Daiichi Sankyo Inc. $3,760.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380988
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381022
Principal investigator 1 Daiichi Sankyo Inc. $1,740.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381122
Principal investigator 1 Daiichi Sankyo Inc. $500.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381156
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381200
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381206
Principal investigator 1 Daiichi Sankyo Inc. $4,340.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381288
Principal investigator 1 Daiichi Sankyo Inc. $115.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381318
Principal investigator 1 Daiichi Sankyo Inc. $3,760.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381322
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381392
Principal investigator 1 Daiichi Sankyo Inc. $5,040.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381572
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381592
Principal investigator 1 Incyte Corporation $85.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586678
Principal investigator 1 Incyte Corporation $85.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586689
Principal investigator 1 Incyte Corporation $85.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586694
Principal investigator 1 Incyte Corporation $85.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586698
Principal investigator 1 Incyte Corporation $85.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586703
Principal investigator 1 Incyte Corporation $85.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586708
Principal investigator 1 Incyte Corporation $594.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586741
Principal investigator 1 Incyte Corporation $594.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586745
Principal investigator 1 Incyte Corporation $594.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586749
Principal investigator 1 Incyte Corporation $594.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586756
Principal investigator 1 Incyte Corporation $594.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586760
Principal investigator 1 Incyte Corporation $594.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586764
Principal investigator 1 Incyte Corporation $379.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586780
Principal investigator 1 Incyte Corporation $379.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586785
Principal investigator 1 Incyte Corporation $3,093.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586814
Principal investigator 1 Incyte Corporation $4,543.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586832
Principal investigator 1 Incyte Corporation $601.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586835
Principal investigator 1 Incyte Corporation $325.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586838
Principal investigator 1 Incyte Corporation $331.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586846
Principal investigator 1 Incyte Corporation $331.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586850
Principal investigator 1 Incyte Corporation $3,074.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586854
Principal investigator 1 Incyte Corporation $3,129.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586868
Principal investigator 1 Incyte Corporation $3,129.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586872
Principal investigator 1 Incyte Corporation $624.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586883
Principal investigator 1 Incyte Corporation $140.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586887
Principal investigator 1 Incyte Corporation $140.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586891
Principal investigator 1 Incyte Corporation $140.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586896
Principal investigator 1 Incyte Corporation $2,850.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586901
Principal investigator 1 Incyte Corporation $89.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586916
Principal investigator 1 Incyte Corporation $197.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586943
Principal investigator 1 Incyte Corporation $197.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586947
Principal investigator 1 Incyte Corporation $197.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586951
Principal investigator 1 Incyte Corporation $197.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586955
Principal investigator 1 Incyte Corporation $371.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586975
Principal investigator 1 Incyte Corporation $371.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586978
Principal investigator 1 Incyte Corporation $1,500.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586987
Principal investigator 1 Incyte Corporation $196.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240587001
Principal investigator 1 Incyte Corporation $196.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240587004
Principal investigator 1 Incyte Corporation $196.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240587009
Principal investigator 1 Incyte Corporation $196.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240587012
Principal investigator 1 Incyte Corporation $196.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240587016
Principal investigator 1 Incyte Corporation $341.71 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240587020
Principal investigator 1 Incyte Corporation $115.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240587029
Principal investigator 1 Incyte Corporation $115.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240587033
Principal investigator 1 Daiichi Sankyo Inc. $45.00 11/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380312
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380348
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380492
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 11/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380594
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380604
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380630
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380660
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380692
Principal investigator 1 Daiichi Sankyo Inc. $46.00 11/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380768
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380772
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380810
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380896
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380940
Principal investigator 1 Daiichi Sankyo Inc. $132.00 11/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381028
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381038
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381236
Principal investigator 1 Daiichi Sankyo Inc. $132.00 11/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381646
Principal investigator 1 Daiichi Sankyo Inc. $115.00 11/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381686
Principal investigator 1 Incyte Corporation $995.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586668
Principal investigator 1 Incyte Corporation $995.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586671
Principal investigator 1 Incyte Corporation $995.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586675
Principal investigator 1 Incyte Corporation $4,805.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586789
Principal investigator 1 Incyte Corporation $4,805.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586793
Principal investigator 1 Incyte Corporation $2,502.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586817
Principal investigator 1 Incyte Corporation $2,502.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586820
Principal investigator 1 Incyte Corporation $4,433.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586920
Principal investigator 1 Incyte Corporation $3,251.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586922
Principal investigator 1 Incyte Corporation $3,251.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586925
Principal investigator 1 Incyte Corporation $2,304.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586960
Principal investigator 1 Incyte Corporation $2,304.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586965
Principal investigator 1 Incyte Corporation $2,304.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586970
Principal investigator 1 Incyte Corporation $4,003.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240587071
Principal investigator 1 Incyte Corporation $4,003.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240587076
Principal investigator 1 Janssen Research & Development, LLC $18,220.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175326942
Principal investigator 1 Daiichi Sankyo Inc. $115.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380266
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380276
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380280
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380332
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380334
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380338
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380342
Principal investigator 1 Daiichi Sankyo Inc. $115.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380354
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380362
Principal investigator 1 Daiichi Sankyo Inc. $45.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380370
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380378
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380386
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380388
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380408
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380474
Principal investigator 1 Daiichi Sankyo Inc. $115.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380490
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380496
Principal investigator 1 Daiichi Sankyo Inc. $115.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380538
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380554
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380558
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380560
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380588
Principal investigator 1 Daiichi Sankyo Inc. $53.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380602
Principal investigator 1 Daiichi Sankyo Inc. $132.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380612
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380614
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380624
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380626
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380628
Principal investigator 1 Daiichi Sankyo Inc. $132.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380642
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380658
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380682
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380684
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380688
Principal investigator 1 Daiichi Sankyo Inc. $132.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380728
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380738
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380748
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380770
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380790
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380822
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380840
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380848
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380860
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380898
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380936
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380942
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380954
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380998
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381002
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381012
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381014
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381036
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381060
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381064
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381074
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381112
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381136
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381144
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381154
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381172
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381220
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381222
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381244
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381250
Principal investigator 1 Daiichi Sankyo Inc. $115.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381254
Principal investigator 1 Daiichi Sankyo Inc. $132.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381260
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381312
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381334
Principal investigator 1 Daiichi Sankyo Inc. $78.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381344
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381346
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381348
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381350
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381366
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381370
Principal investigator 1 Daiichi Sankyo Inc. $115.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381394
Principal investigator 1 Daiichi Sankyo Inc. $115.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381396
Principal investigator 1 Daiichi Sankyo Inc. $115.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381424
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381430
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381436
Principal investigator 1 Daiichi Sankyo Inc. $115.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381438
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381448
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381456
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381476
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381478
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381514
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381534
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381558
Principal investigator 1 Daiichi Sankyo Inc. $115.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381570
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381582
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381588
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381602
Principal investigator 1 Daiichi Sankyo Inc. $184.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381618
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381640
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381642
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381652
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381658
Principal investigator 1 Daiichi Sankyo Inc. $115.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381662
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381676
Principal investigator 1 Daiichi Sankyo Inc. $115.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381692
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 11/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175326741
Principal investigator 1 Janssen Research & Development, LLC $4,500.00 11/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328147
Principal investigator 1 ABBVIE INC. $2,333.00 11/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202523929
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,253.00 11/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220796959
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,043.80 11/13/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220814647
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380400
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380432
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 11/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380576
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380694
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380776
Principal investigator 1 Daiichi Sankyo Inc. $49.00 11/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380778
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380784
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380820
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380944
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381094
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381114
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381176
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381184
Principal investigator 1 Daiichi Sankyo Inc. $132.00 11/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381188
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 11/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381278
Principal investigator 1 Daiichi Sankyo Inc. $1,800.00 11/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381300
Principal investigator 1 Daiichi Sankyo Inc. $1,800.00 11/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381400
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381402
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381608
Principal investigator 1 Daiichi Sankyo Inc. $132.00 11/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381660
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380264
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380298
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380304
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380330
Principal investigator 1 Daiichi Sankyo Inc. $46.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380336
Principal investigator 1 Daiichi Sankyo Inc. $132.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380344
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380416
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380420
Principal investigator 1 Daiichi Sankyo Inc. $115.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380422
Principal investigator 1 Daiichi Sankyo Inc. $115.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380430
Principal investigator 1 Daiichi Sankyo Inc. $157.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380472
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380476
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380518
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380570
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380598
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380606
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380652
Principal investigator 1 Daiichi Sankyo Inc. $115.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380662
Principal investigator 1 Daiichi Sankyo Inc. $46.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380714
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380814
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380836
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380890
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380892
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381088
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381092
Principal investigator 1 Daiichi Sankyo Inc. $46.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381174
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381216
Principal investigator 1 Daiichi Sankyo Inc. $115.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381224
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381274
Principal investigator 1 Daiichi Sankyo Inc. $115.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381276
Principal investigator 1 Daiichi Sankyo Inc. $46.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381404
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381406
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381440
Principal investigator 1 Daiichi Sankyo Inc. $46.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381458
Principal investigator 1 Daiichi Sankyo Inc. $45.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381470
Principal investigator 1 Daiichi Sankyo Inc. $115.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381532
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381548
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381552
Principal investigator 1 Daiichi Sankyo Inc. $46.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381568
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381584
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381616
Principal investigator 1 Daiichi Sankyo Inc. $46.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381624
Principal investigator 1 Daiichi Sankyo Inc. $165.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381664
Principal investigator 1 Daiichi Sankyo Inc. $115.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381694
Principal investigator 1 Daiichi Sankyo Inc. $68.00 11/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381700
Principal investigator 1 Incyte Corporation $197.00 11/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586912
Principal investigator 1 Incyte Corporation $371.00 11/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240587023
Principal investigator 1 Incyte Corporation $3,012.00 11/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240587102
Principal investigator 1 Janssen Research & Development, LLC $64.00 11/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175326756
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 11/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327200
Principal investigator 1 Janssen Research & Development, LLC $2,555.00 11/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327294
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 11/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327312
Principal investigator 1 Janssen Research & Development, LLC $2,555.00 11/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328731
Principal investigator 1 Janssen Research & Development, LLC $2,555.00 11/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175329316
Principal investigator 1 Janssen Research & Development, LLC $2,555.00 11/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175329473
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 11/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175329518
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 11/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175329616
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380278
Principal investigator 1 Daiichi Sankyo Inc. $115.00 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380308
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380446
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380508
Principal investigator 1 Daiichi Sankyo Inc. $49.00 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380520
Principal investigator 1 Daiichi Sankyo Inc. $46.00 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380548
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380716
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380718
Principal investigator 1 Daiichi Sankyo Inc. $115.00 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380754
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380852
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380924
Principal investigator 1 Daiichi Sankyo Inc. $61.00 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380958
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381010
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381052
Principal investigator 1 Daiichi Sankyo Inc. $61.00 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381192
Principal investigator 1 Daiichi Sankyo Inc. $46.00 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381196
Principal investigator 1 Daiichi Sankyo Inc. $176.00 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381298
Principal investigator 1 Daiichi Sankyo Inc. $132.00 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381320
Principal investigator 1 Incyte Corporation $2,850.00 11/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586713
Principal investigator 1 Janssen Research & Development, LLC $47,613.46 11/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 study of JNJ-95437446 in participants with advanced-stage solid tumors No dispute reported 06/30/2026 1175327170
Principal investigator 1 Janssen Research & Development, LLC $2,555.00 11/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327892
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 11/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328230
Principal investigator 1 Janssen Research & Development, LLC $64.00 11/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328796
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 11/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175329794
Principal investigator 1 Daiichi Sankyo Inc. $1,427.00 11/05/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377039
Principal investigator 1 Daiichi Sankyo Inc. $6,573.00 11/05/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377063
Principal investigator 1 Daiichi Sankyo Inc. $5,476.00 11/05/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377069
Principal investigator 1 Daiichi Sankyo Inc. $1,427.00 11/05/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377073
Principal investigator 1 Daiichi Sankyo Inc. $1,427.00 11/05/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377081
Principal investigator 1 Daiichi Sankyo Inc. $1,427.00 11/05/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377099
Principal investigator 1 Hoffmann-La Roche Limited $5,266.00 11/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s) No dispute reported 06/30/2026 1211652812
Principal investigator 1 Hoffmann-La Roche Limited $2,500.00 11/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s) No dispute reported 06/30/2026 1211652817
Principal investigator 1 Hoffmann-La Roche Limited $2,554.00 11/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s) No dispute reported 06/30/2026 1211652823
Principal investigator 1 Hoffmann-La Roche Limited $2,554.00 11/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s) No dispute reported 06/30/2026 1211652828
Principal investigator 1 Hoffmann-La Roche Limited $15,000.00 11/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s) No dispute reported 06/30/2026 1211652836
Principal investigator 1 PFIZER INC. $22,653.32 11/04/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228738705
Principal investigator 1 Daiichi Sankyo Inc. $67.65 11/03/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368401
Principal investigator 1 Daiichi Sankyo Inc. $354.00 11/03/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368403
Principal investigator 1 Daiichi Sankyo Inc. $332.00 11/03/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368411
Principal investigator 1 Daiichi Sankyo Inc. $166.00 11/03/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368413
Principal investigator 1 Daiichi Sankyo Inc. $177.00 11/03/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368423
Principal investigator 1 Daiichi Sankyo Inc. $36.50 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377313
Principal investigator 1 Daiichi Sankyo Inc. $20.85 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377315
Principal investigator 1 Daiichi Sankyo Inc. $37.35 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377317
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377319
Principal investigator 1 Daiichi Sankyo Inc. $20.85 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377321
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377327
Principal investigator 1 Daiichi Sankyo Inc. $37.35 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377329
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377337
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377345
Principal investigator 1 Daiichi Sankyo Inc. $20.85 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377351
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377353
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377359
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377361
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377365
Principal investigator 1 Daiichi Sankyo Inc. $37.35 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377367
Principal investigator 1 Daiichi Sankyo Inc. $62.00 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377369
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377373
Principal investigator 1 Daiichi Sankyo Inc. $46.50 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377375
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377377
Principal investigator 1 Daiichi Sankyo Inc. $109.50 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377379
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377381
Principal investigator 1 Daiichi Sankyo Inc. $20.85 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377383
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377385
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377393
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377395
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377397
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377399
Principal investigator 1 Daiichi Sankyo Inc. $62.55 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377401
Principal investigator 1 Daiichi Sankyo Inc. $86.30 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377409
Principal investigator 1 Daiichi Sankyo Inc. $4.40 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377413
Principal investigator 1 Daiichi Sankyo Inc. $154.65 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377415
Principal investigator 1 Daiichi Sankyo Inc. $37.35 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377417
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377419
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377425
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377427
Principal investigator 1 Daiichi Sankyo Inc. $37.35 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377429
Principal investigator 1 Daiichi Sankyo Inc. $20.85 11/03/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377431
Principal investigator 1 Daiichi Sankyo Inc. $46.00 11/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380644
Principal investigator 1 Hoffmann-La Roche Limited $950.00 11/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s) No dispute reported 06/30/2026 1211652806
Principal investigator 1 Hoffmann-La Roche Limited $203.00 11/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s) No dispute reported 06/30/2026 1211652810
Principal investigator 1 Hoffmann-La Roche Limited $1,500.00 11/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s) No dispute reported 06/30/2026 1211652820
Principal investigator 1 Hoffmann-La Roche Limited $379.00 11/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s) No dispute reported 06/30/2026 1211652832
Principal investigator 1 Janssen Research & Development, LLC $22,370.00 11/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175322889
Principal investigator 1 Janssen Research & Development, LLC $54.00 11/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175327616
Principal investigator 1 Janssen Research & Development, LLC $34,988.00 11/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175328392
Principal investigator 1 Janssen Research & Development, LLC $28,224.10 11/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328746
Principal investigator 1 Janssen Research & Development, LLC $47.00 11/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175329055
Principal investigator 1 Janssen Research & Development, LLC $3,803.00 11/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175329540
Principal investigator 1 BioNTech SE $79.18 11/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists
BNT326-01 No dispute reported 06/30/2026 1249018430
Principal investigator 1 BioNTech SE $25.00 11/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists
BNT326-01 No dispute reported 06/30/2026 1249018432
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
University Of Minnesota Division Of Hematology Oncology And Transplantation
A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) No dispute reported 06/30/2026 1220634899
Principal investigator 1 BioNTech SE $40.00 10/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists
BNT326-01 No dispute reported 06/30/2026 1249018426
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $750.00 10/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer No dispute reported 06/30/2026 1233739069
Principal investigator 1 Janssen Research & Development, LLC $5,400.00 10/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175320204
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 10/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175320475
Principal investigator 1 Janssen Research & Development, LLC $5,400.00 10/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175321427
Principal investigator 1 Janssen Research & Development, LLC $450.00 10/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175326437
Principal investigator 1 BioNTech SE $40.00 10/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists
BNT326-01 No dispute reported 06/30/2026 1249018428
Principal investigator 1 Daiichi Sankyo Inc. $182.00 10/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378305
Principal investigator 1 Daiichi Sankyo Inc. $182.00 10/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378321
Principal investigator 1 Daiichi Sankyo Inc. $182.00 10/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378333
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 10/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378337
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 10/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378355
Principal investigator 1 Daiichi Sankyo Inc. $182.00 10/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378381
Principal investigator 1 Hoffmann-La Roche Limited $5,600.00 10/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s) No dispute reported 06/30/2026 1211652798
Principal investigator 1 Boehringer Ingelheim International GmbH $186.56 10/27/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220640489
Principal investigator 1 Janssen Research & Development, LLC $2,596.00 10/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175327688
Principal investigator 1 Janssen Research & Development, LLC $4,500.00 10/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175327725
Principal investigator 1 Janssen Research & Development, LLC $2,596.00 10/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175328056
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 10/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175328314
Principal investigator 1 Janssen Research & Development, LLC $2,265.00 10/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175328655
Principal investigator 1 Janssen Research & Development, LLC $2,596.00 10/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175329046
Principal investigator 1 Janssen Research & Development, LLC $2,596.00 10/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175329634
Principal investigator 1 PFIZER INC. $1,500.00 10/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228741317
Principal investigator 1 ABBVIE INC. $2,333.00 10/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518033
Principal investigator 1 ABBVIE INC. $1,630.00 10/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518035
Principal investigator 1 Hoffmann-La Roche Limited $16,400.00 10/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s) No dispute reported 06/30/2026 1211652802
Principal investigator 1 Daiichi Sankyo Inc. $138.00 10/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378283
Principal investigator 1 Daiichi Sankyo Inc. $138.00 10/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378301
Principal investigator 1 Daiichi Sankyo Inc. $138.00 10/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378313
Principal investigator 1 Daiichi Sankyo Inc. $138.00 10/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378335
Principal investigator 1 Daiichi Sankyo Inc. $138.00 10/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378343
Principal investigator 1 Daiichi Sankyo Inc. $138.00 10/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378357
Principal investigator 1 Daiichi Sankyo Inc. $138.00 10/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378361
Principal investigator 1 Daiichi Sankyo Inc. $138.00 10/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378367
Principal investigator 1 Daiichi Sankyo Inc. $3,457.00 10/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378379
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175325540
Principal investigator 1 Janssen Research & Development, LLC $2,555.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327436
Principal investigator 1 Janssen Research & Development, LLC $64.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327452
Principal investigator 1 Janssen Research & Development, LLC $64.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327459
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328132
Principal investigator 1 Janssen Research & Development, LLC $2,555.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328482
Principal investigator 1 Janssen Research & Development, LLC $64.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328982
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 10/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175326699
Principal investigator 1 Janssen Research & Development, LLC $1,672.30 10/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327161
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 10/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327474
Principal investigator 1 Janssen Research & Development, LLC $199.00 10/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328329
Principal investigator 1 Janssen Research & Development, LLC $2,555.00 10/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328862
Principal investigator 1 Janssen Research & Development, LLC $64.00 10/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328884
Principal investigator 1 Janssen Research & Development, LLC $64.00 10/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328959
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 10/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175329765
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 10/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380340
Principal investigator 1 Daiichi Sankyo Inc. $3,760.00 10/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380372
Principal investigator 1 Daiichi Sankyo Inc. $53.00 10/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380426
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 10/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380468
Principal investigator 1 Daiichi Sankyo Inc. $1,740.00 10/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380516
Principal investigator 1 Daiichi Sankyo Inc. $2,709.00 10/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380666
Principal investigator 1 Daiichi Sankyo Inc. $107.00 10/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380746
Principal investigator 1 Daiichi Sankyo Inc. $500.00 10/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380756
Principal investigator 1 Daiichi Sankyo Inc. $5,040.00 10/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380766
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 10/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380802
Principal investigator 1 Daiichi Sankyo Inc. $61.00 10/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380826
Principal investigator 1 Daiichi Sankyo Inc. $78.00 10/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380828
Principal investigator 1 Daiichi Sankyo Inc. $78.00 10/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380894
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 10/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380918
Principal investigator 1 Daiichi Sankyo Inc. $500.00 10/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380974
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 10/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380978
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 10/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381048
Principal investigator 1 Daiichi Sankyo Inc. $4,340.00 10/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381078
Principal investigator 1 Daiichi Sankyo Inc. $467.00 10/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381246
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 10/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381262
Principal investigator 1 Daiichi Sankyo Inc. $1,740.00 10/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381280
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 10/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381486
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 10/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381508
Principal investigator 1 Daiichi Sankyo Inc. $2,101.00 10/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381578
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 10/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381594
Principal investigator 1 Daiichi Sankyo Inc. $467.00 10/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381598
Principal investigator 1 Daiichi Sankyo Inc. $3,760.00 10/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381614
Principal investigator 1 Daiichi Sankyo Inc. $1,500.00 10/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380722
Principal investigator 1 Novartis Pharmaceuticals Corporation $60,343.37 10/12/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALIST AND RESEARCH INSTITUTE, LLC
A two-part, Phase 1 dose escalation and expansion followed by a randomized, open-label multicenter, Phase 2 study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard of care in patients w No dispute reported 06/30/2026 1190302243
Principal investigator 1 Eli Lilly and Company $55,065.00 10/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
LONG-TERM SAFETY OF PIRTOBRUTINIB IN PARTICIPANTS FROM STUDY LOXO-BTK-18001 WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA OR NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1187891676
Principal investigator 1 Incyte Corporation $2,502.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586681
Principal investigator 1 Incyte Corporation $2,502.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586685
Principal investigator 1 Incyte Corporation $4,427.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586722
Principal investigator 1 Incyte Corporation $4,427.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586725
Principal investigator 1 Incyte Corporation $7,209.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586767
Principal investigator 1 Incyte Corporation $7,209.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586772
Principal investigator 1 Incyte Corporation $7,209.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586776
Principal investigator 1 Incyte Corporation $4,805.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586825
Principal investigator 1 Incyte Corporation $5,242.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586857
Principal investigator 1 Incyte Corporation $5,242.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586860
Principal investigator 1 Incyte Corporation $5,242.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586864
Principal investigator 1 Incyte Corporation $2,304.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586938
Principal investigator 1 Incyte Corporation $3,251.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586982
Principal investigator 1 Incyte Corporation $4,433.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240586991
Principal investigator 1 Incyte Corporation $6,469.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240587051
Principal investigator 1 Incyte Corporation $6,469.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240587055
Principal investigator 1 Incyte Corporation $6,469.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240587062
Principal investigator 1 Incyte Corporation $3,625.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240587065
Principal investigator 1 Incyte Corporation $2,192.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240587091
Principal investigator 1 Incyte Corporation $2,192.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240587094
Principal investigator 1 Incyte Corporation $2,192.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240587098
Principal investigator 1 Daiichi Sankyo Inc. $5,707.00 10/06/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377109
Principal investigator 1 Janssen Research & Development, LLC $131,516.00 10/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175327708
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378281
Principal investigator 1 Daiichi Sankyo Inc. $4,777.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378285
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378295
Principal investigator 1 Daiichi Sankyo Inc. $182.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378297
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378299
Principal investigator 1 Daiichi Sankyo Inc. $182.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378307
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378309
Principal investigator 1 Daiichi Sankyo Inc. $194.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378311
Principal investigator 1 Daiichi Sankyo Inc. $4,777.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378327
Principal investigator 1 Daiichi Sankyo Inc. $182.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378331
Principal investigator 1 Daiichi Sankyo Inc. $4,777.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378339
Principal investigator 1 Daiichi Sankyo Inc. $194.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378345
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378351
Principal investigator 1 Daiichi Sankyo Inc. $182.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378363
Principal investigator 1 Daiichi Sankyo Inc. $182.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378365
Principal investigator 1 Daiichi Sankyo Inc. $182.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378385
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380268
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380310
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380322
Principal investigator 1 Daiichi Sankyo Inc. $5,040.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380324
Principal investigator 1 Daiichi Sankyo Inc. $235.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380364
Principal investigator 1 Daiichi Sankyo Inc. $143.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380380
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380384
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380396
Principal investigator 1 Daiichi Sankyo Inc. $1,740.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380402
Principal investigator 1 Daiichi Sankyo Inc. $2,709.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380414
Principal investigator 1 Daiichi Sankyo Inc. $4,340.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380450
Principal investigator 1 Daiichi Sankyo Inc. $2,709.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380458
Principal investigator 1 Daiichi Sankyo Inc. $3,760.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380494
Principal investigator 1 Daiichi Sankyo Inc. $3,760.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380550
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380592
Principal investigator 1 Daiichi Sankyo Inc. $5,040.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380616
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380752
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380758
Principal investigator 1 Daiichi Sankyo Inc. $76.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380760
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380818
Principal investigator 1 Daiichi Sankyo Inc. $1,253.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380858
Principal investigator 1 Daiichi Sankyo Inc. $3,760.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380926
Principal investigator 1 Daiichi Sankyo Inc. $3,229.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381120
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381180
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381186
Principal investigator 1 Daiichi Sankyo Inc. $4,340.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381232
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381268
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381296
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381302
Principal investigator 1 Daiichi Sankyo Inc. $76.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381310
Principal investigator 1 Daiichi Sankyo Inc. $3,760.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381358
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381360
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381374
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381382
Principal investigator 1 Daiichi Sankyo Inc. $3,760.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381416
Principal investigator 1 Daiichi Sankyo Inc. $3,229.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381418
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381466
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381472
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381492
Principal investigator 1 Daiichi Sankyo Inc. $68.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381512
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 10/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381590
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 10/01/2025 Non-covered Recipient Entity
University Of Minnesota Division Of Hematology Oncology And Transplantation
A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) No dispute reported 06/30/2026 1220634893
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 10/01/2025 Non-covered Recipient Entity
University Of Minnesota Division Of Hematology Oncology And Transplantation
A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) No dispute reported 06/30/2026 1220634895
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
University Of Minnesota Division Of Hematology Oncology And Transplantation
A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) No dispute reported 06/30/2026 1220634897
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $650.00 10/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220796909
Principal investigator 1 Daiichi Sankyo Inc. $91.22 10/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368253
Principal investigator 1 Daiichi Sankyo Inc. $468.70 10/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368255
Principal investigator 1 Daiichi Sankyo Inc. $54.12 10/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368257
Principal investigator 1 Daiichi Sankyo Inc. $227.10 10/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368405
Principal investigator 1 Daiichi Sankyo Inc. $46.87 10/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368407
Principal investigator 1 Daiichi Sankyo Inc. $234.35 10/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368409
Principal investigator 1 Daiichi Sankyo Inc. $45.61 10/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368417
Principal investigator 1 Daiichi Sankyo Inc. $182.44 10/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368419
Principal investigator 1 Daiichi Sankyo Inc. $309.30 10/01/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377323
Principal investigator 1 Daiichi Sankyo Inc. $31.00 10/01/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377325
Principal investigator 1 Daiichi Sankyo Inc. $62.00 10/01/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377333
Principal investigator 1 Daiichi Sankyo Inc. $18.25 10/01/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377355
Principal investigator 1 Daiichi Sankyo Inc. $31.00 10/01/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377363
Principal investigator 1 Daiichi Sankyo Inc. $15.50 10/01/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377371
Principal investigator 1 Daiichi Sankyo Inc. $20.85 10/01/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377389
Principal investigator 1 Daiichi Sankyo Inc. $37.35 10/01/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377403
Principal investigator 1 Daiichi Sankyo Inc. $31.00 10/01/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377405
Principal investigator 1 BioNTech SE $40.00 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists
BNT326-01 No dispute reported 06/30/2026 1249018424
Principal investigator 1 Incyte Corporation $500.00 09/30/2025 Non-covered Recipient Entity
SARAH CANNON INTEGRATED CANCER SERVICES
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240584867
Principal investigator 1 Incyte Corporation $3,129.00 09/30/2025 Non-covered Recipient Entity
SARAH CANNON INTEGRATED CANCER SERVICES
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240584871
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $750.00 09/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer No dispute reported 06/30/2026 1233739053
Principal investigator 1 Janssen Research & Development, LLC $48,343.00 09/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175323541
Principal investigator 1 Janssen Research & Development, LLC $41,640.75 09/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 study of JNJ-95437446 in participants with advanced-stage solid tumors No dispute reported 06/30/2026 1175327208
Principal investigator 1 Incyte Corporation $341.70 09/25/2025 Non-covered Recipient Entity
SARAH CANNON INTEGRATED CANCER SERVICES
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240584853
Principal investigator 1 Boehringer Ingelheim International GmbH $139.92 09/24/2025 Non-covered Recipient Entity
University Of Minnesota Division Of Hematology Oncology And Transplantation
A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) No dispute reported 06/30/2026 1220634883
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 09/24/2025 Non-covered Recipient Entity
University Of Minnesota Division Of Hematology Oncology And Transplantation
A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) No dispute reported 06/30/2026 1220634885
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 09/24/2025 Non-covered Recipient Entity
University Of Minnesota Division Of Hematology Oncology And Transplantation
A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) No dispute reported 06/30/2026 1220634887
Principal investigator 1 Boehringer Ingelheim International GmbH $5.60 09/24/2025 Non-covered Recipient Entity
University Of Minnesota Division Of Hematology Oncology And Transplantation
A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) No dispute reported 06/30/2026 1220634889
Principal investigator 1 Boehringer Ingelheim International GmbH $5.68 09/24/2025 Non-covered Recipient Entity
University Of Minnesota Division Of Hematology Oncology And Transplantation
A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) No dispute reported 06/30/2026 1220634891
Principal investigator 1 Boehringer Ingelheim International GmbH $2,323.00 09/24/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220640479
Principal investigator 1 Boehringer Ingelheim International GmbH $326.48 09/24/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220640481
Principal investigator 1 Boehringer Ingelheim International GmbH $239.76 09/24/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220640483
Principal investigator 1 Boehringer Ingelheim International GmbH $1,168.00 09/24/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220640485
Principal investigator 1 Boehringer Ingelheim International GmbH $28.80 09/24/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220640487
Principal investigator 1 Incyte Corporation $4,543.00 09/24/2025 Non-covered Recipient Entity
SARAH CANNON INTEGRATED CANCER SERVICES
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240584857
Principal investigator 1 Incyte Corporation $371.00 09/24/2025 Non-covered Recipient Entity
SARAH CANNON INTEGRATED CANCER SERVICES
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240584863
Principal investigator 1 Incyte Corporation $140.00 09/24/2025 Non-covered Recipient Entity
SARAH CANNON INTEGRATED CANCER SERVICES
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240584882
Principal investigator 1 PFIZER INC. $6,300.00 09/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228757410
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,900.00 09/23/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALIST AND RESEARCH INSTITUTE, LLC
A Phase I/Ib, Open-label, Multi-center, Study of QEQ278 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190305359
Principal investigator 1 Janssen Research & Development, LLC $930.60 09/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327670
Principal investigator 1 Janssen Research & Development, LLC $8,500.00 09/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175327884
Principal investigator 1 Janssen Research & Development, LLC $33,000.00 09/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175328406
Principal investigator 1 Janssen Research & Development, LLC $4,137.30 09/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328446
Principal investigator 1 Janssen Research & Development, LLC $2,946.40 09/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328514
Principal investigator 1 Janssen Research & Development, LLC $1,672.30 09/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328938
Principal investigator 1 Janssen Research & Development, LLC $21,977.90 09/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327765
Principal investigator 1 Janssen Research & Development, LLC $22,238.60 09/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328124
Principal investigator 1 Daiichi Sankyo Inc. $4,400.00 09/17/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377005
Principal investigator 1 Daiichi Sankyo Inc. $1,080.00 09/17/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377023
Principal investigator 1 Daiichi Sankyo Inc. $3,457.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378221
Principal investigator 1 Daiichi Sankyo Inc. $3,457.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378229
Principal investigator 1 Daiichi Sankyo Inc. $3,457.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378231
Principal investigator 1 Daiichi Sankyo Inc. $3,457.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378237
Principal investigator 1 Daiichi Sankyo Inc. $3,457.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378243
Principal investigator 1 Daiichi Sankyo Inc. $3,457.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378253
Principal investigator 1 Daiichi Sankyo Inc. $78.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379548
Principal investigator 1 Daiichi Sankyo Inc. $68.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379646
Principal investigator 1 Daiichi Sankyo Inc. $61.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379648
Principal investigator 1 Daiichi Sankyo Inc. $46.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379700
Principal investigator 1 Daiichi Sankyo Inc. $46.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379708
Principal investigator 1 Daiichi Sankyo Inc. $115.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379716
Principal investigator 1 Daiichi Sankyo Inc. $49.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379718
Principal investigator 1 Daiichi Sankyo Inc. $46.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379720
Principal investigator 1 Daiichi Sankyo Inc. $115.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379722
Principal investigator 1 Daiichi Sankyo Inc. $65.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379724
Principal investigator 1 Daiichi Sankyo Inc. $49.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379726
Principal investigator 1 Daiichi Sankyo Inc. $46.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379728
Principal investigator 1 Daiichi Sankyo Inc. $165.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379730
Principal investigator 1 Daiichi Sankyo Inc. $61.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379732
Principal investigator 1 Daiichi Sankyo Inc. $68.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379754
Principal investigator 1 Daiichi Sankyo Inc. $68.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379756
Principal investigator 1 Daiichi Sankyo Inc. $46.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379758
Principal investigator 1 Daiichi Sankyo Inc. $65.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380102
Principal investigator 1 Daiichi Sankyo Inc. $46.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380106
Principal investigator 1 Daiichi Sankyo Inc. $49.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380108
Principal investigator 1 Daiichi Sankyo Inc. $132.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380110
Principal investigator 1 Daiichi Sankyo Inc. $46.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380170
Principal investigator 1 Daiichi Sankyo Inc. $78.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380194
Principal investigator 1 Daiichi Sankyo Inc. $68.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380196
Principal investigator 1 Daiichi Sankyo Inc. $76.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380228
Principal investigator 1 Daiichi Sankyo Inc. $46.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380232
Principal investigator 1 Daiichi Sankyo Inc. $46.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380258
Principal investigator 1 Janssen Research & Development, LLC $2,555.00 09/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327008
Principal investigator 1 Janssen Research & Development, LLC $2,675.00 09/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327243
Principal investigator 1 Janssen Research & Development, LLC $2,555.00 09/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327392
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 09/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327529
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 09/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327799
Principal investigator 1 Janssen Research & Development, LLC $24,124.50 09/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 study of JNJ-95437446 in participants with advanced-stage solid tumors No dispute reported 06/30/2026 1175328556
Principal investigator 1 Janssen Research & Development, LLC $6,000.00 09/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer No dispute reported 06/30/2026 1175328705
Principal investigator 1 Janssen Research & Development, LLC $2,555.00 09/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175329407
Principal investigator 1 Daiichi Sankyo Inc. $46.00 09/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379868
Principal investigator 1 Daiichi Sankyo Inc. $115.00 09/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379870
Principal investigator 1 Daiichi Sankyo Inc. $76.00 09/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379872
Principal investigator 1 Daiichi Sankyo Inc. $49.00 09/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379874
Principal investigator 1 Daiichi Sankyo Inc. $76.00 09/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379876
Principal investigator 1 Daiichi Sankyo Inc. $78.00 09/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379902
Principal investigator 1 Janssen Research & Development, LLC $199.00 09/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327420
Principal investigator 1 Janssen Research & Development, LLC $199.00 09/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328422
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 09/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175329191
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 09/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175329304
Principal investigator 1 Daiichi Sankyo Inc. $1,427.00 09/11/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377007
Principal investigator 1 Daiichi Sankyo Inc. $1,427.00 09/11/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377009
Principal investigator 1 Daiichi Sankyo Inc. $4,815.00 09/11/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377011
Principal investigator 1 Daiichi Sankyo Inc. $7,861.00 09/11/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377013
Principal investigator 1 Daiichi Sankyo Inc. $3,045.00 09/11/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377015
Principal investigator 1 Daiichi Sankyo Inc. $2,443.00 09/11/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377017
Principal investigator 1 Incyte Corporation $2,502.00 09/11/2025 Non-covered Recipient Entity
SARAH CANNON INTEGRATED CANCER SERVICES
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240584808
Principal investigator 1 Incyte Corporation $995.00 09/11/2025 Non-covered Recipient Entity
SARAH CANNON INTEGRATED CANCER SERVICES
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240584812
Principal investigator 1 Incyte Corporation $4,805.00 09/11/2025 Non-covered Recipient Entity
SARAH CANNON INTEGRATED CANCER SERVICES
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240584816
Principal investigator 1 Incyte Corporation $7,209.00 09/11/2025 Non-covered Recipient Entity
SARAH CANNON INTEGRATED CANCER SERVICES
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240584819
Principal investigator 1 Incyte Corporation $3,251.00 09/11/2025 Non-covered Recipient Entity
SARAH CANNON INTEGRATED CANCER SERVICES
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240584824
Principal investigator 1 Incyte Corporation $3,475.00 09/11/2025 Non-covered Recipient Entity
SARAH CANNON INTEGRATED CANCER SERVICES
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240584828
Principal investigator 1 Incyte Corporation $2,304.00 09/11/2025 Non-covered Recipient Entity
SARAH CANNON INTEGRATED CANCER SERVICES
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240584831
Principal investigator 1 Incyte Corporation $2,192.00 09/11/2025 Non-covered Recipient Entity
SARAH CANNON INTEGRATED CANCER SERVICES
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240584835
Principal investigator 1 Incyte Corporation $4,433.00 09/11/2025 Non-covered Recipient Entity
SARAH CANNON INTEGRATED CANCER SERVICES
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240584838
Principal investigator 1 Incyte Corporation $995.00 09/11/2025 Non-covered Recipient Entity
SARAH CANNON INTEGRATED CANCER SERVICES
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240584842
Principal investigator 1 Incyte Corporation $5,242.00 09/11/2025 Non-covered Recipient Entity
SARAH CANNON INTEGRATED CANCER SERVICES
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240584845
Principal investigator 1 Incyte Corporation $4,003.00 09/11/2025 Non-covered Recipient Entity
SARAH CANNON INTEGRATED CANCER SERVICES
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240584850
Principal investigator 1 Incyte Corporation $6,469.00 09/11/2025 Non-covered Recipient Entity
SARAH CANNON INTEGRATED CANCER SERVICES
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240584874
Principal investigator 1 Incyte Corporation $6,469.00 09/11/2025 Non-covered Recipient Entity
SARAH CANNON INTEGRATED CANCER SERVICES
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240584878
Principal investigator 1 Incyte Corporation $995.00 09/11/2025 Non-covered Recipient Entity
SARAH CANNON INTEGRATED CANCER SERVICES
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240584887
Principal investigator 1 Incyte Corporation $995.00 09/11/2025 Non-covered Recipient Entity
SARAH CANNON INTEGRATED CANCER SERVICES
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240584892
Principal investigator 1 Incyte Corporation $995.00 09/11/2025 Non-covered Recipient Entity
SARAH CANNON INTEGRATED CANCER SERVICES
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240584897
Principal investigator 1 Incyte Corporation $3,251.00 09/11/2025 Non-covered Recipient Entity
SARAH CANNON INTEGRATED CANCER SERVICES
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240584901
Principal investigator 1 Incyte Corporation $4,003.00 09/11/2025 Non-covered Recipient Entity
SARAH CANNON INTEGRATED CANCER SERVICES
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240584905
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,589.30 09/11/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALIST AND RESEARCH INSTITUTE, LLC
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma No dispute reported 06/30/2026 1190305357
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $787.50 09/10/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220796957
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $600.00 09/10/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220814639
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,728.70 09/10/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220814641
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $600.00 09/10/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220814643
Principal investigator 1 Genentech, Inc. $1,275.00 09/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211651779
Principal investigator 1 Genentech, Inc. $1,045.00 09/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211651929
Principal investigator 1 SANOFI US SERVICES INC. $2,500.00 09/10/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1226082018
Principal investigator 1 Daiichi Sankyo Inc. $53.00 09/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379446
Principal investigator 1 Daiichi Sankyo Inc. $49.00 09/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379898
Principal investigator 1 Daiichi Sankyo Inc. $165.00 09/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379900
Principal investigator 1 Daiichi Sankyo Inc. $115.00 09/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379942
Principal investigator 1 Daiichi Sankyo Inc. $46.00 09/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379944
Principal investigator 1 Daiichi Sankyo Inc. $115.00 09/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379948
Principal investigator 1 Daiichi Sankyo Inc. $68.00 09/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379950
Principal investigator 1 Daiichi Sankyo Inc. $53.00 09/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379960
Principal investigator 1 Daiichi Sankyo Inc. $165.00 09/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379962
Principal investigator 1 Daiichi Sankyo Inc. $46.00 09/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379966
Principal investigator 1 Daiichi Sankyo Inc. $46.00 09/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379968
Principal investigator 1 Daiichi Sankyo Inc. $115.00 09/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379970
Principal investigator 1 Daiichi Sankyo Inc. $46.00 09/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379972
Principal investigator 1 Daiichi Sankyo Inc. $46.00 09/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379974
Principal investigator 1 Daiichi Sankyo Inc. $53.00 09/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379976
Principal investigator 1 Daiichi Sankyo Inc. $61.00 09/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379978
Principal investigator 1 Daiichi Sankyo Inc. $61.00 09/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379980
Principal investigator 1 Daiichi Sankyo Inc. $78.00 09/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379982
Principal investigator 1 Daiichi Sankyo Inc. $68.00 09/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379984
Principal investigator 1 Daiichi Sankyo Inc. $65.00 09/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379986
Principal investigator 1 Daiichi Sankyo Inc. $115.00 09/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379988
Principal investigator 1 Daiichi Sankyo Inc. $53.00 09/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379990
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 09/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379992
Principal investigator 1 Daiichi Sankyo Inc. $49.00 09/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380188
Principal investigator 1 Janssen Research & Development, LLC $7,500.00 09/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175323489
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 09/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175324077
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 09/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175326429
Principal investigator 1 Daiichi Sankyo Inc. $2,300.00 09/05/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379440
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,400.00 09/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220814645
Principal investigator 1 Daiichi Sankyo Inc. $468.70 09/03/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368241
Principal investigator 1 Daiichi Sankyo Inc. $46.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379412
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379864
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379866
Principal investigator 1 Daiichi Sankyo Inc. $68.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379894
Principal investigator 1 Daiichi Sankyo Inc. $61.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379896
Principal investigator 1 Daiichi Sankyo Inc. $65.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379904
Principal investigator 1 Daiichi Sankyo Inc. $46.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379994
Principal investigator 1 Daiichi Sankyo Inc. $46.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380050
Principal investigator 1 Daiichi Sankyo Inc. $49.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380052
Principal investigator 1 Daiichi Sankyo Inc. $46.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380054
Principal investigator 1 Daiichi Sankyo Inc. $78.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380056
Principal investigator 1 Daiichi Sankyo Inc. $68.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380060
Principal investigator 1 Daiichi Sankyo Inc. $68.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380062
Principal investigator 1 Daiichi Sankyo Inc. $115.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380064
Principal investigator 1 Daiichi Sankyo Inc. $46.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380066
Principal investigator 1 Daiichi Sankyo Inc. $165.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380068
Principal investigator 1 Daiichi Sankyo Inc. $176.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380112
Principal investigator 1 Daiichi Sankyo Inc. $115.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380114
Principal investigator 1 Daiichi Sankyo Inc. $46.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380116
Principal investigator 1 Daiichi Sankyo Inc. $46.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380118
Principal investigator 1 Daiichi Sankyo Inc. $450.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380120
Principal investigator 1 Daiichi Sankyo Inc. $115.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380122
Principal investigator 1 Daiichi Sankyo Inc. $115.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380124
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380126
Principal investigator 1 Daiichi Sankyo Inc. $176.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380128
Principal investigator 1 Daiichi Sankyo Inc. $65.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380130
Principal investigator 1 Daiichi Sankyo Inc. $65.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380198
Principal investigator 1 Daiichi Sankyo Inc. $61.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380212
Principal investigator 1 SANOFI US SERVICES INC. $2,500.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institution Llc
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1226147763
Principal investigator 1 ABBVIE INC. $2,126.25 09/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506743
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
University Of Minnesota Division Of Hematology Oncology And Transplantation
A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) No dispute reported 06/30/2026 1220634875
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 09/01/2025 Non-covered Recipient Entity
University Of Minnesota Division Of Hematology Oncology And Transplantation
A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) No dispute reported 06/30/2026 1220634877
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 09/01/2025 Non-covered Recipient Entity
University Of Minnesota Division Of Hematology Oncology And Transplantation
A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) No dispute reported 06/30/2026 1220634879
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 09/01/2025 Non-covered Recipient Entity
University Of Minnesota Division Of Hematology Oncology And Transplantation
A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) No dispute reported 06/30/2026 1220634881
Principal investigator 1 Boehringer Ingelheim International GmbH $1,567.31 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639494
Principal investigator 1 Boehringer Ingelheim International GmbH $3,048.50 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639496
Principal investigator 1 Boehringer Ingelheim International GmbH $1,235.81 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639498
Principal investigator 1 Boehringer Ingelheim International GmbH $1,526.69 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639500
Principal investigator 1 Eli Lilly and Company $33,406.50 08/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS
LONG-TERM SAFETY OF PIRTOBRUTINIB IN PARTICIPANTS FROM STUDY LOXO-BTK-18001 WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA OR NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1187880077
Principal investigator 1 Eli Lilly and Company $255,856.81 08/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS
A FIRST-IN-HUMAN, PHASE 1A/1B TRIAL TO ASSESS THE SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF LY4175408, AN ANTIBODY DRUG CONJUGATE TARGETING PROTEIN TYROSINE KINASE 7-EXPRESSING TUMOR CELLS, IN PARTICIPANTS WITH SELECTED ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1187881178
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $750.00 08/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer No dispute reported 06/30/2026 1233739055
Principal investigator 1 Novartis Pharmaceuticals Corporation $422.50 08/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALIST AND RESEARCH INSTITUTE, LLC
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma No dispute reported 06/30/2026 1190301687
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,500.00 08/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALIST AND RESEARCH INSTITUTE, LLC
A Phase I/Ib, Open-label, Multi-center, Study of QEQ278 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190301689
Principal investigator 1 BioNTech SE $40.00 08/29/2025 Non-covered Recipient Entity
Florida Cancer Specialists
BNT326-01 No dispute reported 06/30/2026 1249018418
Principal investigator 1 Janssen Research & Development, LLC $11,391.00 08/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175319851
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,234.60 08/27/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220814637
Principal investigator 1 SANOFI US SERVICES INC. $1,312.88 08/27/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1226082022
Principal investigator 1 Daiichi Sankyo Inc. $450.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379796
Principal investigator 1 Daiichi Sankyo Inc. $264.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379798
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379800
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379802
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379804
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379806
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379906
Principal investigator 1 Daiichi Sankyo Inc. $450.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379908
Principal investigator 1 Daiichi Sankyo Inc. $68.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379910
Principal investigator 1 Daiichi Sankyo Inc. $65.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379912
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379914
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379916
Principal investigator 1 Daiichi Sankyo Inc. $65.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379918
Principal investigator 1 Daiichi Sankyo Inc. $65.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379920
Principal investigator 1 Daiichi Sankyo Inc. $2,101.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379922
Principal investigator 1 Daiichi Sankyo Inc. $132.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379924
Principal investigator 1 Daiichi Sankyo Inc. $65.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379926
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379928
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379930
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379932
Principal investigator 1 Daiichi Sankyo Inc. $4,601.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379934
Principal investigator 1 Daiichi Sankyo Inc. $65.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379936
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379938
Principal investigator 1 Daiichi Sankyo Inc. $189.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379940
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379946
Principal investigator 1 Daiichi Sankyo Inc. $450.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379952
Principal investigator 1 Daiichi Sankyo Inc. $65.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379954
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379956
Principal investigator 1 Daiichi Sankyo Inc. $46.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379958
Principal investigator 1 Daiichi Sankyo Inc. $132.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379964
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379996
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379998
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380000
Principal investigator 1 Daiichi Sankyo Inc. $132.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380002
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380004
Principal investigator 1 Daiichi Sankyo Inc. $68.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380006
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380008
Principal investigator 1 Daiichi Sankyo Inc. $65.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380010
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380012
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380014
Principal investigator 1 Daiichi Sankyo Inc. $68.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380016
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380018
Principal investigator 1 Daiichi Sankyo Inc. $68.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380020
Principal investigator 1 Daiichi Sankyo Inc. $68.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380022
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380024
Principal investigator 1 Daiichi Sankyo Inc. $450.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380026
Principal investigator 1 Daiichi Sankyo Inc. $450.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380028
Principal investigator 1 Daiichi Sankyo Inc. $68.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380030
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380032
Principal investigator 1 Daiichi Sankyo Inc. $46.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380034
Principal investigator 1 Daiichi Sankyo Inc. $68.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380036
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380038
Principal investigator 1 Daiichi Sankyo Inc. $450.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380040
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380042
Principal investigator 1 Daiichi Sankyo Inc. $157.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380044
Principal investigator 1 Daiichi Sankyo Inc. $4,601.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380172
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380184
Principal investigator 1 Daiichi Sankyo Inc. $68.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380234
Principal investigator 1 Daiichi Sankyo Inc. $65.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380240
Principal investigator 1 Daiichi Sankyo Inc. $68.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380242
Principal investigator 1 Daiichi Sankyo Inc. $68.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380244
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380254
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 08/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327862
Principal investigator 1 Janssen Research & Development, LLC $757.00 08/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328257
Principal investigator 1 Janssen Research & Development, LLC $4,500.00 08/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175329077
Principal investigator 1 Janssen Research & Development, LLC $171.00 08/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175319750
Principal investigator 1 Janssen Research & Development, LLC $66.00 08/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175320406
Principal investigator 1 Janssen Research & Development, LLC $151.00 08/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175320500
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 08/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175320611
Principal investigator 1 Janssen Research & Development, LLC $33,000.00 08/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175320633
Principal investigator 1 Janssen Research & Development, LLC $151.00 08/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175321144
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 08/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175321368
Principal investigator 1 Janssen Research & Development, LLC $214.00 08/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175321407
Principal investigator 1 Janssen Research & Development, LLC $197.00 08/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175321799
Principal investigator 1 Janssen Research & Development, LLC $130.00 08/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175322097
Principal investigator 1 Janssen Research & Development, LLC $151.00 08/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175322105
Principal investigator 1 Janssen Research & Development, LLC $151.00 08/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175323033
Principal investigator 1 Janssen Research & Development, LLC $151.00 08/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175323300
Principal investigator 1 Janssen Research & Development, LLC $51.00 08/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175323337
Principal investigator 1 Janssen Research & Development, LLC $61.00 08/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175324106
Principal investigator 1 Janssen Research & Development, LLC $151.00 08/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175325911
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 08/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175326495
Principal investigator 1 Janssen Research & Development, LLC $449.00 08/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175326683
Principal investigator 1 Janssen Research & Development, LLC $148.00 08/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328951
Principal investigator 1 PFIZER INC. $6,600.00 08/22/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228761577
Principal investigator 1 ABBVIE INC. $2,333.00 08/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202505231
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 08/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380046
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 08/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380048
Principal investigator 1 Novartis Pharmaceuticals Corporation $205,443.37 08/19/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALIST AND RESEARCH INSTITUTE, LLC
An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors No dispute reported 06/30/2026 1190305355
Principal investigator 1 Daiichi Sankyo Inc. $325.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379414
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379416
Principal investigator 1 Daiichi Sankyo Inc. $2,600.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379418
Principal investigator 1 Daiichi Sankyo Inc. $68.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379420
Principal investigator 1 Daiichi Sankyo Inc. $65.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379422
Principal investigator 1 Daiichi Sankyo Inc. $65.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379424
Principal investigator 1 Daiichi Sankyo Inc. $65.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379426
Principal investigator 1 Daiichi Sankyo Inc. $230.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379428
Principal investigator 1 Daiichi Sankyo Inc. $805.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379430
Principal investigator 1 Daiichi Sankyo Inc. $6,396.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379432
Principal investigator 1 Daiichi Sankyo Inc. $46.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379434
Principal investigator 1 Daiichi Sankyo Inc. $46.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379436
Principal investigator 1 Daiichi Sankyo Inc. $45.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379438
Principal investigator 1 Daiichi Sankyo Inc. $68.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379442
Principal investigator 1 Daiichi Sankyo Inc. $390.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379444
Principal investigator 1 Daiichi Sankyo Inc. $112.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379450
Principal investigator 1 Daiichi Sankyo Inc. $390.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379452
Principal investigator 1 Daiichi Sankyo Inc. $6,396.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379454
Principal investigator 1 Daiichi Sankyo Inc. $68.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379456
Principal investigator 1 Daiichi Sankyo Inc. $68.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379458
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379460
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379462
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379464
Principal investigator 1 Daiichi Sankyo Inc. $1,056.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379466
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379468
Principal investigator 1 Daiichi Sankyo Inc. $630.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379472
Principal investigator 1 Daiichi Sankyo Inc. $1,800.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379474
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379476
Principal investigator 1 Daiichi Sankyo Inc. $4,264.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379478
Principal investigator 1 Daiichi Sankyo Inc. $460.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379480
Principal investigator 1 Daiichi Sankyo Inc. $4,264.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379482
Principal investigator 1 Daiichi Sankyo Inc. $46.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379484
Principal investigator 1 Daiichi Sankyo Inc. $46.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379486
Principal investigator 1 Daiichi Sankyo Inc. $476.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379488
Principal investigator 1 Daiichi Sankyo Inc. $805.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379490
Principal investigator 1 Daiichi Sankyo Inc. $112.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379492
Principal investigator 1 Daiichi Sankyo Inc. $4,264.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379494
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379496
Principal investigator 1 Daiichi Sankyo Inc. $53.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379498
Principal investigator 1 Daiichi Sankyo Inc. $61.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379500
Principal investigator 1 Daiichi Sankyo Inc. $4,264.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379504
Principal investigator 1 Daiichi Sankyo Inc. $78.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379506
Principal investigator 1 Daiichi Sankyo Inc. $2,600.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379508
Principal investigator 1 Daiichi Sankyo Inc. $49.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379510
Principal investigator 1 Daiichi Sankyo Inc. $1,800.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379512
Principal investigator 1 Daiichi Sankyo Inc. $390.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379514
Principal investigator 1 Daiichi Sankyo Inc. $450.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379516
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379518
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379520
Principal investigator 1 Daiichi Sankyo Inc. $184.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379522
Principal investigator 1 Daiichi Sankyo Inc. $46.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379524
Principal investigator 1 Daiichi Sankyo Inc. $46.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379526
Principal investigator 1 Daiichi Sankyo Inc. $65.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379528
Principal investigator 1 Daiichi Sankyo Inc. $136.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379532
Principal investigator 1 Daiichi Sankyo Inc. $450.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379538
Principal investigator 1 Daiichi Sankyo Inc. $45.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379540
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379544
Principal investigator 1 Daiichi Sankyo Inc. $230.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379550
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379552
Principal investigator 1 Daiichi Sankyo Inc. $46.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379554
Principal investigator 1 Daiichi Sankyo Inc. $2,101.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379556
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379558
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379560
Principal investigator 1 Daiichi Sankyo Inc. $46.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379564
Principal investigator 1 Daiichi Sankyo Inc. $230.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379566
Principal investigator 1 Daiichi Sankyo Inc. $2,132.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379568
Principal investigator 1 Daiichi Sankyo Inc. $2,101.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379572
Principal investigator 1 Daiichi Sankyo Inc. $195.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379574
Principal investigator 1 Daiichi Sankyo Inc. $165.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379576
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379578
Principal investigator 1 Daiichi Sankyo Inc. $345.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379580
Principal investigator 1 Daiichi Sankyo Inc. $45.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379582
Principal investigator 1 Daiichi Sankyo Inc. $46.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379584
Principal investigator 1 Daiichi Sankyo Inc. $630.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379586
Principal investigator 1 Daiichi Sankyo Inc. $112.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379588
Principal investigator 1 Daiichi Sankyo Inc. $53.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379590
Principal investigator 1 Daiichi Sankyo Inc. $2,132.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379610
Principal investigator 1 Daiichi Sankyo Inc. $45.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379616
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379620
Principal investigator 1 Daiichi Sankyo Inc. $46.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379622
Principal investigator 1 Daiichi Sankyo Inc. $65.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379624
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379632
Principal investigator 1 Daiichi Sankyo Inc. $1,800.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379638
Principal investigator 1 Daiichi Sankyo Inc. $630.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379640
Principal investigator 1 Daiichi Sankyo Inc. $112.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379642
Principal investigator 1 Daiichi Sankyo Inc. $46.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379644
Principal investigator 1 Daiichi Sankyo Inc. $46.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379650
Principal investigator 1 Daiichi Sankyo Inc. $46.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379670
Principal investigator 1 Daiichi Sankyo Inc. $45.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379674
Principal investigator 1 Daiichi Sankyo Inc. $112.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379676
Principal investigator 1 Daiichi Sankyo Inc. $65.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379680
Principal investigator 1 Daiichi Sankyo Inc. $1,800.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379682
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379684
Principal investigator 1 Daiichi Sankyo Inc. $45.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379686
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379688
Principal investigator 1 Daiichi Sankyo Inc. $65.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379690
Principal investigator 1 Daiichi Sankyo Inc. $68.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379692
Principal investigator 1 Daiichi Sankyo Inc. $68.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379694
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379696
Principal investigator 1 Daiichi Sankyo Inc. $2,132.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379698
Principal investigator 1 Daiichi Sankyo Inc. $112.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379734
Principal investigator 1 Daiichi Sankyo Inc. $408.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379736
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379738
Principal investigator 1 Daiichi Sankyo Inc. $690.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379740
Principal investigator 1 Daiichi Sankyo Inc. $45.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379742
Principal investigator 1 Daiichi Sankyo Inc. $46.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379744
Principal investigator 1 Daiichi Sankyo Inc. $390.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379746
Principal investigator 1 Daiichi Sankyo Inc. $792.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379748
Principal investigator 1 Daiichi Sankyo Inc. $5,000.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379750
Principal investigator 1 Daiichi Sankyo Inc. $65.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379752
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379760
Principal investigator 1 Daiichi Sankyo Inc. $46.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379762
Principal investigator 1 Daiichi Sankyo Inc. $46.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379764
Principal investigator 1 Daiichi Sankyo Inc. $165.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379766
Principal investigator 1 Daiichi Sankyo Inc. $45.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379768
Principal investigator 1 Daiichi Sankyo Inc. $136.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379770
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379772
Principal investigator 1 Daiichi Sankyo Inc. $130.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379774
Principal investigator 1 Daiichi Sankyo Inc. $46.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379776
Principal investigator 1 Daiichi Sankyo Inc. $68.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379778
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379780
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379782
Principal investigator 1 Daiichi Sankyo Inc. $136.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379784
Principal investigator 1 Daiichi Sankyo Inc. $2,600.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379786
Principal investigator 1 Daiichi Sankyo Inc. $230.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379788
Principal investigator 1 Daiichi Sankyo Inc. $230.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379790
Principal investigator 1 Daiichi Sankyo Inc. $792.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379792
Principal investigator 1 Daiichi Sankyo Inc. $518.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379794
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379808
Principal investigator 1 Daiichi Sankyo Inc. $450.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379810
Principal investigator 1 Daiichi Sankyo Inc. $65.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379812
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379814
Principal investigator 1 Daiichi Sankyo Inc. $68.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379816
Principal investigator 1 Daiichi Sankyo Inc. $132.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379818
Principal investigator 1 Daiichi Sankyo Inc. $46.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379820
Principal investigator 1 Daiichi Sankyo Inc. $630.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379824
Principal investigator 1 Daiichi Sankyo Inc. $2,132.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379832
Principal investigator 1 Daiichi Sankyo Inc. $2,132.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379838
Principal investigator 1 Daiichi Sankyo Inc. $2,600.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379846
Principal investigator 1 Daiichi Sankyo Inc. $1,800.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379848
Principal investigator 1 Daiichi Sankyo Inc. $112.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379856
Principal investigator 1 Daiichi Sankyo Inc. $630.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379858
Principal investigator 1 Daiichi Sankyo Inc. $690.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379882
Principal investigator 1 Daiichi Sankyo Inc. $408.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379884
Principal investigator 1 Daiichi Sankyo Inc. $130.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379886
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379888
Principal investigator 1 Daiichi Sankyo Inc. $165.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379890
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380164
Principal investigator 1 Daiichi Sankyo Inc. $2,132.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380176
Principal investigator 1 Daiichi Sankyo Inc. $2,132.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380178
Principal investigator 1 Daiichi Sankyo Inc. $46.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380186
Principal investigator 1 Daiichi Sankyo Inc. $46.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380190
Principal investigator 1 Daiichi Sankyo Inc. $2,600.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380204
Principal investigator 1 Daiichi Sankyo Inc. $748.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380206
Principal investigator 1 Daiichi Sankyo Inc. $2,132.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380208
Principal investigator 1 Daiichi Sankyo Inc. $2,132.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380210
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380214
Principal investigator 1 Daiichi Sankyo Inc. $46.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380216
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380218
Principal investigator 1 Daiichi Sankyo Inc. $272.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380222
Principal investigator 1 Daiichi Sankyo Inc. $2,132.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380226
Principal investigator 1 Daiichi Sankyo Inc. $195.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380236
Principal investigator 1 Daiichi Sankyo Inc. $204.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380238
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380246
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380250
Principal investigator 1 Daiichi Sankyo Inc. $630.00 08/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380256
Principal investigator 1 Incyte Corporation $601.00 08/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586591
Principal investigator 1 Incyte Corporation $2,850.00 08/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586629
Principal investigator 1 Janssen Research & Development, LLC $151.00 08/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175319948
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 08/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175319958
Principal investigator 1 Janssen Research & Development, LLC $66.00 08/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175319974
Principal investigator 1 Janssen Research & Development, LLC $49.00 08/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175320062
Principal investigator 1 Janssen Research & Development, LLC $47.00 08/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175321636
Principal investigator 1 Janssen Research & Development, LLC $49.00 08/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175321716
Principal investigator 1 Janssen Research & Development, LLC $151.00 08/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175321974
Principal investigator 1 Janssen Research & Development, LLC $608.00 08/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175323564
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 08/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175324359
Principal investigator 1 Janssen Research & Development, LLC $81.00 08/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175324658
Principal investigator 1 Janssen Research & Development, LLC $151.00 08/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175324748
Principal investigator 1 Janssen Research & Development, LLC $14,952.36 08/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175324915
Principal investigator 1 Janssen Research & Development, LLC $59.00 08/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175325173
Principal investigator 1 Janssen Research & Development, LLC $151.00 08/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175326414
Principal investigator 1 BioNTech SE $15.84 08/17/2025 Non-covered Recipient Entity
Florida Cancer Specialists
BNT326-01 No dispute reported 06/30/2026 1249018420
Principal investigator 1 BioNTech SE $25.00 08/17/2025 Non-covered Recipient Entity
Florida Cancer Specialists
BNT326-01 No dispute reported 06/30/2026 1249018422
Principal investigator 1 Daiichi Sankyo Inc. $3,760.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380070
Principal investigator 1 Daiichi Sankyo Inc. $1,740.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380072
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380074
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380076
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380078
Principal investigator 1 Daiichi Sankyo Inc. $3,760.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380080
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380082
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380084
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380086
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380088
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380090
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380224
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 08/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380230
Principal investigator 1 Incyte Corporation $7,209.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586553
Principal investigator 1 Incyte Corporation $2,192.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586557
Principal investigator 1 Incyte Corporation $2,502.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586561
Principal investigator 1 Incyte Corporation $2,304.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586565
Principal investigator 1 Incyte Corporation $3,625.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586570
Principal investigator 1 Incyte Corporation $3,625.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586574
Principal investigator 1 Incyte Corporation $2,502.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586578
Principal investigator 1 Incyte Corporation $4,805.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586582
Principal investigator 1 Incyte Corporation $4,805.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586586
Principal investigator 1 Incyte Corporation $5,242.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586612
Principal investigator 1 Incyte Corporation $5,242.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586615
Principal investigator 1 Daiichi Sankyo Inc. $61.00 08/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379702
Principal investigator 1 Daiichi Sankyo Inc. $61.00 08/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379704
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379706
Principal investigator 1 Daiichi Sankyo Inc. $450.00 08/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379710
Principal investigator 1 Daiichi Sankyo Inc. $112.00 08/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379712
Principal investigator 1 Daiichi Sankyo Inc. $65.00 08/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379714
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 08/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380174
Principal investigator 1 Daiichi Sankyo Inc. $182.00 08/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378223
Principal investigator 1 Daiichi Sankyo Inc. $182.00 08/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378225
Principal investigator 1 Daiichi Sankyo Inc. $194.00 08/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378271
Principal investigator 1 Janssen Research & Development, LLC $4,600.00 08/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327816
Principal investigator 1 Daiichi Sankyo Inc. $182.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378191
Principal investigator 1 Daiichi Sankyo Inc. $4,777.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378195
Principal investigator 1 Daiichi Sankyo Inc. $182.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378197
Principal investigator 1 Daiichi Sankyo Inc. $4,777.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378199
Principal investigator 1 Daiichi Sankyo Inc. $182.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378201
Principal investigator 1 Daiichi Sankyo Inc. $182.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378203
Principal investigator 1 Daiichi Sankyo Inc. $182.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378205
Principal investigator 1 Daiichi Sankyo Inc. $182.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378207
Principal investigator 1 Daiichi Sankyo Inc. $4,777.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378209
Principal investigator 1 Daiichi Sankyo Inc. $50.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378227
Principal investigator 1 Daiichi Sankyo Inc. $182.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378277
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379410
Principal investigator 1 Daiichi Sankyo Inc. $65.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379448
Principal investigator 1 Daiichi Sankyo Inc. $65.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379470
Principal investigator 1 Daiichi Sankyo Inc. $184.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379530
Principal investigator 1 Daiichi Sankyo Inc. $2,101.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379534
Principal investigator 1 Daiichi Sankyo Inc. $450.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379536
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379542
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379546
Principal investigator 1 Daiichi Sankyo Inc. $450.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379562
Principal investigator 1 Daiichi Sankyo Inc. $2,101.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379570
Principal investigator 1 Daiichi Sankyo Inc. $68.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379592
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379594
Principal investigator 1 Daiichi Sankyo Inc. $68.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379596
Principal investigator 1 Daiichi Sankyo Inc. $450.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379598
Principal investigator 1 Daiichi Sankyo Inc. $1,800.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379600
Principal investigator 1 Daiichi Sankyo Inc. $2,101.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379602
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379604
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379606
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379612
Principal investigator 1 Daiichi Sankyo Inc. $46.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379614
Principal investigator 1 Daiichi Sankyo Inc. $65.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379618
Principal investigator 1 Daiichi Sankyo Inc. $132.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379626
Principal investigator 1 Daiichi Sankyo Inc. $53.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379628
Principal investigator 1 Daiichi Sankyo Inc. $68.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379630
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379634
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379636
Principal investigator 1 Daiichi Sankyo Inc. $78.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379652
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379654
Principal investigator 1 Daiichi Sankyo Inc. $450.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379656
Principal investigator 1 Daiichi Sankyo Inc. $450.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379658
Principal investigator 1 Daiichi Sankyo Inc. $68.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379660
Principal investigator 1 Daiichi Sankyo Inc. $450.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379662
Principal investigator 1 Daiichi Sankyo Inc. $450.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379664
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379666
Principal investigator 1 Daiichi Sankyo Inc. $450.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379668
Principal investigator 1 Daiichi Sankyo Inc. $46.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379672
Principal investigator 1 Daiichi Sankyo Inc. $450.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379678
Principal investigator 1 Daiichi Sankyo Inc. $68.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379828
Principal investigator 1 Daiichi Sankyo Inc. $132.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379840
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379842
Principal investigator 1 Daiichi Sankyo Inc. $68.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379844
Principal investigator 1 Daiichi Sankyo Inc. $46.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379850
Principal investigator 1 Daiichi Sankyo Inc. $53.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379852
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379854
Principal investigator 1 Daiichi Sankyo Inc. $46.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379860
Principal investigator 1 Daiichi Sankyo Inc. $49.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379862
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379878
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379880
Principal investigator 1 Daiichi Sankyo Inc. $450.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379892
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380162
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380166
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380168
Principal investigator 1 Daiichi Sankyo Inc. $68.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380180
Principal investigator 1 Daiichi Sankyo Inc. $132.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380192
Principal investigator 1 Daiichi Sankyo Inc. $176.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380220
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380248
Principal investigator 1 Daiichi Sankyo Inc. $165.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380252
Principal investigator 1 Daiichi Sankyo Inc. $132.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380260
Principal investigator 1 Genentech, Inc. $2,427.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211651724
Principal investigator 1 Genentech, Inc. $7,247.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211651732
Principal investigator 1 Genentech, Inc. $2,410.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211651743
Principal investigator 1 Genentech, Inc. $847.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211652032
Principal investigator 1 Genentech, Inc. $21,741.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211652047
Principal investigator 1 Genentech, Inc. $8,318.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211652055
Principal investigator 1 Genentech, Inc. $2,410.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211652179
Principal investigator 1 Genentech, Inc. $375.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211652236
Principal investigator 1 Genentech, Inc. $7,247.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211652336
Principal investigator 1 Incyte Corporation $2,192.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586339
Principal investigator 1 Incyte Corporation $7,209.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586342
Principal investigator 1 Incyte Corporation $7,209.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586355
Principal investigator 1 Incyte Corporation $3,251.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586358
Principal investigator 1 Incyte Corporation $2,192.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586362
Principal investigator 1 Incyte Corporation $2,502.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586366
Principal investigator 1 Incyte Corporation $2,502.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586371
Principal investigator 1 Incyte Corporation $6,469.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586375
Principal investigator 1 Incyte Corporation $6,469.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586379
Principal investigator 1 Incyte Corporation $2,304.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586382
Principal investigator 1 Incyte Corporation $4,805.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586387
Principal investigator 1 Incyte Corporation $7,209.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586395
Principal investigator 1 Incyte Corporation $3,251.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586398
Principal investigator 1 Incyte Corporation $2,192.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586402
Principal investigator 1 Incyte Corporation $2,502.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586406
Principal investigator 1 Incyte Corporation $2,502.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586411
Principal investigator 1 Incyte Corporation $6,469.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586417
Principal investigator 1 Incyte Corporation $6,469.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586421
Principal investigator 1 Incyte Corporation $2,304.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586424
Principal investigator 1 Incyte Corporation $2,304.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586433
Principal investigator 1 Incyte Corporation $4,805.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586437
Principal investigator 1 Incyte Corporation $7,209.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586441
Principal investigator 1 Incyte Corporation $2,192.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586445
Principal investigator 1 Incyte Corporation $5,242.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586449
Principal investigator 1 Incyte Corporation $5,242.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586454
Principal investigator 1 Incyte Corporation $4,433.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586634
Principal investigator 1 Incyte Corporation $4,433.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586643
Principal investigator 1 Incyte Corporation $3,251.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586647
Principal investigator 1 Incyte Corporation $3,251.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586653
Principal investigator 1 Incyte Corporation $5,242.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586660
Principal investigator 1 Incyte Corporation $5,242.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586664
Principal investigator 1 Janssen Research & Development, LLC $63,409.00 08/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175323100
Principal investigator 1 Daiichi Sankyo Inc. $2,800.00 08/07/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377003
Principal investigator 1 Daiichi Sankyo Inc. $215.00 08/07/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377019
Principal investigator 1 Daiichi Sankyo Inc. $15,400.00 08/07/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377021
Principal investigator 1 Incyte Corporation $1,500.00 08/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586459
Principal investigator 1 Incyte Corporation $5,700.00 08/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586463
Principal investigator 1 Incyte Corporation $379.00 08/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586467
Principal investigator 1 Incyte Corporation $14,500.00 08/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586471
Principal investigator 1 Incyte Corporation $1,049.52 08/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586475
Principal investigator 1 Incyte Corporation $5,000.00 08/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586480
Principal investigator 1 Incyte Corporation $13,000.00 08/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586595
Principal investigator 1 Incyte Corporation $140.00 08/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586599
Principal investigator 1 Incyte Corporation $2,850.00 08/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586625
Principal investigator 1 ABBVIE INC. $116.10 08/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202503027
Principal investigator 1 Daiichi Sankyo Inc. $26.30 08/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368199
Principal investigator 1 Daiichi Sankyo Inc. $35.40 08/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368201
Principal investigator 1 Daiichi Sankyo Inc. $26.30 08/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368203
Principal investigator 1 Daiichi Sankyo Inc. $26.30 08/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368205
Principal investigator 1 Daiichi Sankyo Inc. $26.30 08/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368207
Principal investigator 1 Daiichi Sankyo Inc. $26.30 08/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368209
Principal investigator 1 Daiichi Sankyo Inc. $26.30 08/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368211
Principal investigator 1 Daiichi Sankyo Inc. $26.30 08/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368213
Principal investigator 1 Daiichi Sankyo Inc. $26.30 08/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368215
Principal investigator 1 Daiichi Sankyo Inc. $26.30 08/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368217
Principal investigator 1 Daiichi Sankyo Inc. $26.30 08/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368219
Principal investigator 1 Daiichi Sankyo Inc. $35.40 08/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368221
Principal investigator 1 Daiichi Sankyo Inc. $26.30 08/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368223
Principal investigator 1 Daiichi Sankyo Inc. $26.30 08/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368225
Principal investigator 1 Daiichi Sankyo Inc. $26.30 08/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368227
Principal investigator 1 Daiichi Sankyo Inc. $26.30 08/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368229
Principal investigator 1 Daiichi Sankyo Inc. $26.30 08/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368231
Principal investigator 1 Daiichi Sankyo Inc. $26.30 08/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368233
Principal investigator 1 Daiichi Sankyo Inc. $26.30 08/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368235
Principal investigator 1 Daiichi Sankyo Inc. $26.30 08/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368237
Principal investigator 1 Daiichi Sankyo Inc. $35.40 08/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368239
Principal investigator 1 Daiichi Sankyo Inc. $26.30 08/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368247
Principal investigator 1 Daiichi Sankyo Inc. $35.40 08/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368249
Principal investigator 1 Daiichi Sankyo Inc. $35.40 08/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368251
Principal investigator 1 Daiichi Sankyo Inc. $197.25 08/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368375
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 08/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175319193
Principal investigator 1 Janssen Research & Development, LLC $6,000.00 08/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175320934
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,000.00 08/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220796953
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,600.00 08/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220796955
Principal investigator 1 Daiichi Sankyo Inc. $364.00 08/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378239
Principal investigator 1 Daiichi Sankyo Inc. $910.00 08/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378241
Principal investigator 1 Daiichi Sankyo Inc. $3,219.00 08/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378245
Principal investigator 1 Daiichi Sankyo Inc. $5,192.00 08/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378247
Principal investigator 1 Daiichi Sankyo Inc. $1,552.00 08/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378249
Principal investigator 1 Daiichi Sankyo Inc. $42,993.00 08/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378251
Principal investigator 1 Daiichi Sankyo Inc. $1,274.00 08/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378257
Principal investigator 1 Daiichi Sankyo Inc. $194.00 08/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378259
Principal investigator 1 Daiichi Sankyo Inc. $364.00 08/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378261
Principal investigator 1 Daiichi Sankyo Inc. $2,181.00 08/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378263
Principal investigator 1 Daiichi Sankyo Inc. $2,730.00 08/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378265
Principal investigator 1 BioNTech SE $40.00 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists
BNT326-01 No dispute reported 06/30/2026 1249018412
Principal investigator 1 Boehringer Ingelheim International GmbH $1,433.25 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639474
Principal investigator 1 Boehringer Ingelheim International GmbH $2,914.44 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639476
Principal investigator 1 Boehringer Ingelheim International GmbH $951.44 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639478
Principal investigator 1 Boehringer Ingelheim International GmbH $1,392.63 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639480
Principal investigator 1 Boehringer Ingelheim International GmbH $1,860.95 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639482
Principal investigator 1 Boehringer Ingelheim International GmbH $1,950.00 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639484
Principal investigator 1 Boehringer Ingelheim International GmbH $65.00 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639486
Principal investigator 1 Boehringer Ingelheim International GmbH $203.13 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639488
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639490
Principal investigator 1 Boehringer Ingelheim International GmbH $800.00 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639492
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $750.00 07/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer No dispute reported 06/30/2026 1233739051
Principal investigator 1 Janssen Research & Development, LLC $168,179.20 07/31/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175326748
Principal investigator 1 Novartis Pharmaceuticals Corporation $27,269.33 07/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALIST AND RESEARCH INSTITUTE, LLC
An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors No dispute reported 06/30/2026 1190301685
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 07/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378233
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 07/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378235
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 07/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378273
Principal investigator 1 Daiichi Sankyo Inc. $76.00 07/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380182
Principal investigator 1 Incyte Corporation $197.00 07/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586484
Principal investigator 1 Incyte Corporation $601.00 07/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586488
Principal investigator 1 Incyte Corporation $140.00 07/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586494
Principal investigator 1 Incyte Corporation $140.00 07/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586498
Principal investigator 1 Incyte Corporation $325.00 07/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586501
Principal investigator 1 Incyte Corporation $325.00 07/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586505
Principal investigator 1 Incyte Corporation $594.00 07/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586508
Principal investigator 1 Incyte Corporation $594.00 07/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586511
Principal investigator 1 Incyte Corporation $379.00 07/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586518
Principal investigator 1 Incyte Corporation $197.00 07/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586521
Principal investigator 1 Incyte Corporation $601.00 07/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586525
Principal investigator 1 Incyte Corporation $85.00 07/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586530
Principal investigator 1 Incyte Corporation $4,543.00 07/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586536
Principal investigator 1 Incyte Corporation $325.00 07/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586541
Principal investigator 1 Incyte Corporation $594.00 07/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586545
Principal investigator 1 Incyte Corporation $379.00 07/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586548
Principal investigator 1 Incyte Corporation $115.00 07/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586603
Principal investigator 1 Incyte Corporation $115.00 07/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586607
Principal investigator 1 Incyte Corporation $197.00 07/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586619
Principal investigator 1 ABBVIE INC. $2,333.00 07/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202499274
Principal investigator 1 Daiichi Sankyo Inc. $115.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378211
Principal investigator 1 Daiichi Sankyo Inc. $4,777.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378213
Principal investigator 1 Daiichi Sankyo Inc. $65.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378215
Principal investigator 1 Daiichi Sankyo Inc. $182.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378217
Principal investigator 1 Daiichi Sankyo Inc. $97.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378219
Principal investigator 1 Daiichi Sankyo Inc. $4,777.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378279
Principal investigator 1 Janssen Research & Development, LLC $151.00 07/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175319295
Principal investigator 1 Janssen Research & Development, LLC $500.00 07/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175320907
Principal investigator 1 Janssen Research & Development, LLC $151.00 07/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175321780
Principal investigator 1 Janssen Research & Development, LLC $151.00 07/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175323641
Principal investigator 1 Janssen Research & Development, LLC $151.00 07/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175324968
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 07/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175325557
Principal investigator 1 Janssen Research & Development, LLC $151.00 07/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175325779
Principal investigator 1 Genentech, Inc. $2,000.00 07/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph1 evaluating G6036 in pts with a KRAS Mutation No dispute reported 06/30/2026 1211651937
Principal investigator 1 ABBVIE INC. $2,131.00 07/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202498504
Principal investigator 1 ABBVIE INC. $78.30 07/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202498506
Principal investigator 1 ABBVIE INC. $2,131.00 07/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202498508
Principal investigator 1 ABBVIE INC. $78.30 07/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202498510
Principal investigator 1 ABBVIE INC. $2,131.00 07/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202498330
Principal investigator 1 Daiichi Sankyo Inc. $3,457.00 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378255
Principal investigator 1 Daiichi Sankyo Inc. $1,299.00 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378267
Principal investigator 1 Daiichi Sankyo Inc. $6,728.00 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378269
Principal investigator 1 Daiichi Sankyo Inc. $3,457.00 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378275
Principal investigator 1 Daiichi Sankyo Inc. $170.00 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380058
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380092
Principal investigator 1 Daiichi Sankyo Inc. $1,740.00 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380094
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380096
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380098
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380100
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380104
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380132
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380134
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380136
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380138
Principal investigator 1 Daiichi Sankyo Inc. $3,760.00 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380140
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380142
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380144
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380146
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380148
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380150
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380152
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380154
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380156
Principal investigator 1 Daiichi Sankyo Inc. $3,760.00 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380158
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380160
Principal investigator 1 Genentech, Inc. $195.92 07/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211651654
Principal investigator 1 Genentech, Inc. $1,007.46 07/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211651720
Principal investigator 1 Genentech, Inc. $416.64 07/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211651934
Principal investigator 1 Genentech, Inc. $4,775.00 07/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211651985
Principal investigator 1 Genentech, Inc. $122.08 07/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211652108
Principal investigator 1 Incyte Corporation $3,129.00 07/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586346
Principal investigator 1 Incyte Corporation $85.00 07/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586352
Principal investigator 1 Incyte Corporation $85.00 07/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586391
Principal investigator 1 Incyte Corporation $115.00 07/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. No dispute reported 06/30/2026 1240586657
Principal investigator 1 Daiichi Sankyo Inc. $2,181.00 07/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378193
Principal investigator 1 Daiichi Sankyo Inc. $68.00 07/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379502
Principal investigator 1 Daiichi Sankyo Inc. $115.00 07/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379822
Principal investigator 1 Daiichi Sankyo Inc. $78.00 07/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379826
Principal investigator 1 Daiichi Sankyo Inc. $132.00 07/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379830
Principal investigator 1 Daiichi Sankyo Inc. $68.00 07/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379834
Principal investigator 1 Daiichi Sankyo Inc. $46.00 07/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379836
Principal investigator 1 Daiichi Sankyo Inc. $157.00 07/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380200
Principal investigator 1 Daiichi Sankyo Inc. $65.00 07/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223380202
Principal investigator 1 Genentech, Inc. $847.00 07/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211651851
Principal investigator 1 Genentech, Inc. $1,565.00 07/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph1 evaluating G6036 in pts with a KRAS Mutation No dispute reported 06/30/2026 1211652085
Principal investigator 1 Genentech, Inc. $7,247.00 07/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211652090
Principal investigator 1 Genentech, Inc. $847.00 07/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211652166
Principal investigator 1 PFIZER INC. $54.00 07/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228788053
Principal investigator 1 Janssen Research & Development, LLC $2,555.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327919
Principal investigator 1 Janssen Research & Development, LLC $2,555.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328043
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328578
Principal investigator 1 Janssen Research & Development, LLC $379.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175329500
Principal investigator 1 BioNTech SE $203.99 07/09/2025 Non-covered Recipient Entity
Florida Cancer Specialists
BNT326-01 No dispute reported 06/30/2026 1249018410
Principal investigator 1 Blueprint Medicines Corporation $2,500.00 07/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1235784963
Principal investigator 1 Blueprint Medicines Corporation $2,500.00 07/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1235784977
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,576.70 07/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220796951
Principal investigator 1 Janssen Research & Development, LLC $2,555.00 07/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175326886
Principal investigator 1 Janssen Research & Development, LLC $2,555.00 07/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327604
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 07/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327899
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 07/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328006
Principal investigator 1 Janssen Research & Development, LLC $2,555.00 07/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328166
Principal investigator 1 Janssen Research & Development, LLC $2,555.00 07/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328381
Principal investigator 1 Janssen Research & Development, LLC $2,555.00 07/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328458
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 07/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328603
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 07/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328686
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 07/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328854
Principal investigator 1 Janssen Research & Development, LLC $64.00 07/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175329687
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 07/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175329720
Principal investigator 1 BioNTech SE $25.00 07/07/2025 Non-covered Recipient Entity
Florida Cancer Specialists
BNT326-01 No dispute reported 06/30/2026 1249018414
Principal investigator 1 BioNTech SE $95.01 07/07/2025 Non-covered Recipient Entity
Florida Cancer Specialists
BNT326-01 No dispute reported 06/30/2026 1249018416
Principal investigator 1 Daiichi Sankyo Inc. $132.00 07/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379608
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 07/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327662
Principal investigator 1 Janssen Research & Development, LLC $2,555.00 07/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328321
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 07/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328399
Principal investigator 1 Janssen Research & Development, LLC $1,275.00 07/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328812
Principal investigator 1 Daiichi Sankyo Inc. $52.60 07/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368193
Principal investigator 1 Daiichi Sankyo Inc. $70.80 07/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368195
Principal investigator 1 Daiichi Sankyo Inc. $52.60 07/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368197
Principal investigator 1 Daiichi Sankyo Inc. $13.53 07/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368243
Principal investigator 1 Daiichi Sankyo Inc. $182.44 07/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368245
Principal investigator 1 Daiichi Sankyo Inc. $65.75 07/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368377
Principal investigator 1 Daiichi Sankyo Inc. $35.90 07/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368379
Principal investigator 1 Daiichi Sankyo Inc. $11.90 07/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368381
Principal investigator 1 Daiichi Sankyo Inc. $65.75 07/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368383
Principal investigator 1 Daiichi Sankyo Inc. $65.75 07/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368385
Principal investigator 1 Daiichi Sankyo Inc. $131.50 07/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368387
Principal investigator 1 Daiichi Sankyo Inc. $65.75 07/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368389
Principal investigator 1 Daiichi Sankyo Inc. $65.75 07/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368391
Principal investigator 1 Daiichi Sankyo Inc. $88.50 07/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368393
Principal investigator 1 Daiichi Sankyo Inc. $354.00 07/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368395
Principal investigator 1 Daiichi Sankyo Inc. $30.30 07/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368397
Principal investigator 1 Daiichi Sankyo Inc. $131.50 07/01/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368399
Principal investigator 1 Genentech, Inc. $830.00 07/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph1 evaluating G6036 in pts with a KRAS Mutation No dispute reported 06/30/2026 1211651923
Principal investigator 1 ABBVIE INC. $2,333.00 06/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493623
Principal investigator 1 Boehringer Ingelheim International GmbH $845.00 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639470
Principal investigator 1 Boehringer Ingelheim International GmbH $650.00 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639472
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $250.00 06/30/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220814635
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $750.00 06/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer No dispute reported 06/30/2026 1233739057
Principal investigator 1 Janssen Research & Development, LLC $63,962.00 06/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175325487
Principal investigator 1 Janssen Research & Development, LLC $16,159.80 06/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175329600
Principal investigator 1 ABBVIE INC. $3,436.43 06/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493319
Principal investigator 1 ABBVIE INC. $3,561.30 06/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493331
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,500.00 06/27/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220796905
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,600.00 06/27/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220796907
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,500.00 06/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220816872
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $650.00 06/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220816874
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 06/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175321435
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 06/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175323934
Principal investigator 1 PFIZER INC. $3,300.00 06/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228776590
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378724
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378728
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378734
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378736
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378738
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378740
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378742
Principal investigator 1 Daiichi Sankyo Inc. $500.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378744
Principal investigator 1 Daiichi Sankyo Inc. $4,703.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378746
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378748
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378750
Principal investigator 1 Daiichi Sankyo Inc. $4,703.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378752
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378754
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378756
Principal investigator 1 Daiichi Sankyo Inc. $4,703.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378758
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378760
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378762
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378764
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378804
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378808
Principal investigator 1 Daiichi Sankyo Inc. $3,229.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378828
Principal investigator 1 Daiichi Sankyo Inc. $4,703.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378830
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378832
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378834
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378836
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378838
Principal investigator 1 Daiichi Sankyo Inc. $3,229.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378840
Principal investigator 1 Daiichi Sankyo Inc. $4,703.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378842
Principal investigator 1 Daiichi Sankyo Inc. $500.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378902
Principal investigator 1 Daiichi Sankyo Inc. $500.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378904
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378906
Principal investigator 1 Daiichi Sankyo Inc. $500.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378908
Principal investigator 1 Daiichi Sankyo Inc. $3,760.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378910
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378912
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378914
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378916
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378918
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378920
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378922
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378924
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378926
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378928
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378930
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378966
Principal investigator 1 Daiichi Sankyo Inc. $3,229.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378968
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378970
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378972
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378974
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378976
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379016
Principal investigator 1 Daiichi Sankyo Inc. $4,703.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379018
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379020
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379022
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379024
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379026
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379028
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379030
Principal investigator 1 Daiichi Sankyo Inc. $4,703.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379032
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379034
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379174
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379176
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379178
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379182
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379184
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379186
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379188
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379190
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379192
Principal investigator 1 Daiichi Sankyo Inc. $4,703.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379194
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379196
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379290
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379294
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379316
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379320
Principal investigator 1 Daiichi Sankyo Inc. $2,709.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379326
Principal investigator 1 Daiichi Sankyo Inc. $4,703.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379390
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 06/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379404
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 06/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175327837
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 06/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328804
Principal investigator 1 Janssen Research & Development, LLC $3,200.00 06/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175329433
Principal investigator 1 Daiichi Sankyo Inc. $1,638.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378115
Principal investigator 1 Daiichi Sankyo Inc. $3,564.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378117
Principal investigator 1 Daiichi Sankyo Inc. $270.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378119
Principal investigator 1 Daiichi Sankyo Inc. $138.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378121
Principal investigator 1 Daiichi Sankyo Inc. $270.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378125
Principal investigator 1 Daiichi Sankyo Inc. $1,656.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378127
Principal investigator 1 Daiichi Sankyo Inc. $7,032.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378129
Principal investigator 1 Daiichi Sankyo Inc. $138.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378131
Principal investigator 1 Daiichi Sankyo Inc. $182.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378135
Principal investigator 1 Daiichi Sankyo Inc. $182.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378137
Principal investigator 1 Daiichi Sankyo Inc. $194.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378139
Principal investigator 1 Daiichi Sankyo Inc. $182.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378141
Principal investigator 1 Daiichi Sankyo Inc. $194.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378143
Principal investigator 1 Daiichi Sankyo Inc. $6,241.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378145
Principal investigator 1 Daiichi Sankyo Inc. $270.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378147
Principal investigator 1 Daiichi Sankyo Inc. $3,564.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378149
Principal investigator 1 Daiichi Sankyo Inc. $176.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378151
Principal investigator 1 Daiichi Sankyo Inc. $138.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378153
Principal investigator 1 Daiichi Sankyo Inc. $138.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378159
Principal investigator 1 Daiichi Sankyo Inc. $3,564.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378161
Principal investigator 1 Daiichi Sankyo Inc. $3,564.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378165
Principal investigator 1 Daiichi Sankyo Inc. $138.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378167
Principal investigator 1 Daiichi Sankyo Inc. $138.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378169
Principal investigator 1 Daiichi Sankyo Inc. $372.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378171
Principal investigator 1 Daiichi Sankyo Inc. $182.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378173
Principal investigator 1 Daiichi Sankyo Inc. $182.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378175
Principal investigator 1 Daiichi Sankyo Inc. $3,457.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378177
Principal investigator 1 Daiichi Sankyo Inc. $3,457.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378179
Principal investigator 1 Daiichi Sankyo Inc. $4,777.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378181
Principal investigator 1 Daiichi Sankyo Inc. $3,457.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378185
Principal investigator 1 Daiichi Sankyo Inc. $3,457.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378187
Principal investigator 1 Daiichi Sankyo Inc. $2,700.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379002
Principal investigator 1 Daiichi Sankyo Inc. $13,000.00 06/20/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379386
Principal investigator 1 Blueprint Medicines Corporation $2,500.00 06/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1235784883
Principal investigator 1 Daiichi Sankyo Inc. $182.00 06/18/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378163
Principal investigator 1 Merck Sharp & Dohme LLC $71,860.00 06/18/2025 Non-covered Recipient Entity
Florida cancer specialist -DDU
A Phase 1b,2 Open-Label, Dose Escalation of ADG106 in Combination with Pembrolizumab Anti PD-1 Antibody and Expansion of ADG106 with or without Pembrolizumab in Patients with Advanced or Metastatic Solid and,or Hematological Malignancies No dispute reported 06/30/2026 1232932297
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,575.00 06/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220796949
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,000.00 06/16/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220814633
Principal investigator 1 Daiichi Sankyo Inc. $1,000.00 06/16/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223376989
Principal investigator 1 Daiichi Sankyo Inc. $3,177.00 06/16/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223376991
Principal investigator 1 Daiichi Sankyo Inc. $1,100.00 06/16/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223376993
Principal investigator 1 Daiichi Sankyo Inc. $2,600.00 06/16/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223376995
Principal investigator 1 Daiichi Sankyo Inc. $1,800.00 06/16/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223376997
Principal investigator 1 Daiichi Sankyo Inc. $1,000.00 06/16/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223376999
Principal investigator 1 Daiichi Sankyo Inc. $23,697.00 06/16/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377001
Principal investigator 1 PFIZER INC. $317.25 06/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228791566
Principal investigator 1 ABBVIE INC. $2,333.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202490803
Principal investigator 1 ABBVIE INC. $1,060.00 06/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202490805
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 06/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378113
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 06/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378123
Principal investigator 1 Daiichi Sankyo Inc. $4,777.00 06/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378155
Principal investigator 1 Daiichi Sankyo Inc. $182.00 06/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378157
Principal investigator 1 Daiichi Sankyo Inc. $450.00 06/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379254
Principal investigator 1 Daiichi Sankyo Inc. $488.32 06/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379260
Principal investigator 1 Incyte Corporation $3,500.00 06/09/2025 Non-covered Recipient Entity
FLORIDA CANCER CENTER & RESEARCH INSTITUTE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240535197
Principal investigator 1 Incyte Corporation $23,000.00 06/09/2025 Non-covered Recipient Entity
FLORIDA CANCER CENTER & RESEARCH INSTITUTE
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240535202
Principal investigator 1 SANOFI US SERVICES INC. $190.00 06/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies No dispute reported 06/30/2026 1226082006
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 06/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175321990
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 06/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175325953
Principal investigator 1 Janssen Research & Development, LLC $6,975.00 06/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175328974
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 06/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175329667
Principal investigator 1 ABBVIE INC. $520.12 06/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202490207
Principal investigator 1 ABBVIE INC. $4,994.00 06/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202490239
Principal investigator 1 ABBVIE INC. $260.06 06/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202490241
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,600.00 06/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220816868
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,800.00 06/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220816870
Principal investigator 1 Daiichi Sankyo Inc. $115.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378726
Principal investigator 1 Daiichi Sankyo Inc. $65.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378730
Principal investigator 1 Daiichi Sankyo Inc. $68.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378732
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378766
Principal investigator 1 Daiichi Sankyo Inc. $68.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378768
Principal investigator 1 Daiichi Sankyo Inc. $68.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378770
Principal investigator 1 Daiichi Sankyo Inc. $2,132.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378772
Principal investigator 1 Daiichi Sankyo Inc. $2,132.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378774
Principal investigator 1 Daiichi Sankyo Inc. $115.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378776
Principal investigator 1 Daiichi Sankyo Inc. $115.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378778
Principal investigator 1 Daiichi Sankyo Inc. $2,132.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378780
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378782
Principal investigator 1 Daiichi Sankyo Inc. $115.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378784
Principal investigator 1 Daiichi Sankyo Inc. $115.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378786
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378788
Principal investigator 1 Daiichi Sankyo Inc. $2,132.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378790
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378792
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378794
Principal investigator 1 Daiichi Sankyo Inc. $5,100.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378796
Principal investigator 1 Daiichi Sankyo Inc. $2,132.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378798
Principal investigator 1 Daiichi Sankyo Inc. $65.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378810
Principal investigator 1 Daiichi Sankyo Inc. $46.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378812
Principal investigator 1 Daiichi Sankyo Inc. $45.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378816
Principal investigator 1 Daiichi Sankyo Inc. $68.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378818
Principal investigator 1 Daiichi Sankyo Inc. $46.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378844
Principal investigator 1 Daiichi Sankyo Inc. $450.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378848
Principal investigator 1 Daiichi Sankyo Inc. $65.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378850
Principal investigator 1 Daiichi Sankyo Inc. $115.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378852
Principal investigator 1 Daiichi Sankyo Inc. $65.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378854
Principal investigator 1 Daiichi Sankyo Inc. $157.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378856
Principal investigator 1 Daiichi Sankyo Inc. $157.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378858
Principal investigator 1 Daiichi Sankyo Inc. $115.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378860
Principal investigator 1 Daiichi Sankyo Inc. $68.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378862
Principal investigator 1 Daiichi Sankyo Inc. $65.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379036
Principal investigator 1 Daiichi Sankyo Inc. $68.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379230
Principal investigator 1 Daiichi Sankyo Inc. $68.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379234
Principal investigator 1 Daiichi Sankyo Inc. $115.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379318
Principal investigator 1 Daiichi Sankyo Inc. $2,132.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379336
Principal investigator 1 Daiichi Sankyo Inc. $68.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379348
Principal investigator 1 Daiichi Sankyo Inc. $65.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379350
Principal investigator 1 Daiichi Sankyo Inc. $68.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379356
Principal investigator 1 Daiichi Sankyo Inc. $2,132.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379364
Principal investigator 1 Daiichi Sankyo Inc. $68.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379368
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379384
Principal investigator 1 Daiichi Sankyo Inc. $2,132.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379388
Principal investigator 1 Janssen Research & Development, LLC $115,386.00 06/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175321019
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $400.00 06/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220796903
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,700.00 06/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220796947
Principal investigator 1 Boehringer Ingelheim International GmbH $1,235.81 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639434
Principal investigator 1 Boehringer Ingelheim International GmbH $1,526.69 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639436
Principal investigator 1 Boehringer Ingelheim International GmbH $3,362.94 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639438
Principal investigator 1 Boehringer Ingelheim International GmbH $1,235.81 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639440
Principal investigator 1 Boehringer Ingelheim International GmbH $1,995.50 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639442
Principal investigator 1 Boehringer Ingelheim International GmbH $1,093.63 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639444
Principal investigator 1 Boehringer Ingelheim International GmbH $1,567.31 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639446
Principal investigator 1 Boehringer Ingelheim International GmbH $886.44 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639448
Principal investigator 1 Boehringer Ingelheim International GmbH $3,048.50 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639450
Principal investigator 1 Boehringer Ingelheim International GmbH $1,235.81 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639452
Principal investigator 1 Boehringer Ingelheim International GmbH $802.75 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639454
Principal investigator 1 Boehringer Ingelheim International GmbH $1,629.88 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639456
Principal investigator 1 Boehringer Ingelheim International GmbH $2,146.63 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639458
Principal investigator 1 Boehringer Ingelheim International GmbH $568.75 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639460
Principal investigator 1 Boehringer Ingelheim International GmbH $345.31 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639462
Principal investigator 1 Boehringer Ingelheim International GmbH $1,943.50 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639464
Principal investigator 1 Boehringer Ingelheim International GmbH $1,567.31 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639466
Principal investigator 1 Boehringer Ingelheim International GmbH $3,048.50 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639468
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $750.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer No dispute reported 06/30/2026 1233739059
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $750.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer No dispute reported 06/30/2026 1233739061
Principal investigator 1 Incyte Corporation $1,700.00 05/30/2025 Non-covered Recipient Entity
FCS - CATTLEMEN
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma No dispute reported 06/30/2026 1240534014
Principal investigator 1 Incyte Corporation $650.00 05/30/2025 Non-covered Recipient Entity
FCS - CATTLEMEN
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma No dispute reported 06/30/2026 1240534017
Principal investigator 1 ABBVIE INC. $3,561.30 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202486373
Principal investigator 1 ABBVIE INC. $1,791.45 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202486377
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $129.60 05/27/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220814631
Principal investigator 1 Genentech, Inc. $66.00 05/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph1 evaluating G6036 in pts with a KRAS Mutation No dispute reported 06/30/2026 1211651027
Principal investigator 1 Genentech, Inc. $25.00 05/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph1 evaluating G6036 in pts with a KRAS Mutation No dispute reported 06/30/2026 1211651614
Principal investigator 1 Daiichi Sankyo Inc. $65.00 05/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379152
Principal investigator 1 PFIZER INC. $3,300.00 05/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228773087
Principal investigator 1 Genentech, Inc. $532.44 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph1 evaluating G6036 in pts with a KRAS Mutation No dispute reported 06/30/2026 1211650933
Principal investigator 1 Genentech, Inc. $574.20 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph1 evaluating G6036 in pts with a KRAS Mutation No dispute reported 06/30/2026 1211651115
Principal investigator 1 Genentech, Inc. $15.00 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph1 evaluating G6036 in pts with a KRAS Mutation No dispute reported 06/30/2026 1211651206
Principal investigator 1 Genentech, Inc. $356.16 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph1 evaluating G6036 in pts with a KRAS Mutation No dispute reported 06/30/2026 1211651358
Principal investigator 1 Blueprint Medicines Corporation $665.28 05/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1235784867
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378722
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378864
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378870
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378872
Principal investigator 1 Daiichi Sankyo Inc. $3,229.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378876
Principal investigator 1 Daiichi Sankyo Inc. $2,709.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378878
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378882
Principal investigator 1 Daiichi Sankyo Inc. $3,229.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378884
Principal investigator 1 Daiichi Sankyo Inc. $2,709.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378888
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378892
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378894
Principal investigator 1 Daiichi Sankyo Inc. $4,340.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378896
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378898
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378900
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378932
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378934
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378938
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378942
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378944
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378946
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378948
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378950
Principal investigator 1 Daiichi Sankyo Inc. $3,229.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378952
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378956
Principal investigator 1 Daiichi Sankyo Inc. $5,040.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378988
Principal investigator 1 Daiichi Sankyo Inc. $5,040.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378990
Principal investigator 1 Daiichi Sankyo Inc. $5,040.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378992
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378994
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379040
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379042
Principal investigator 1 Daiichi Sankyo Inc. $2,709.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379044
Principal investigator 1 Daiichi Sankyo Inc. $4,340.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379046
Principal investigator 1 Daiichi Sankyo Inc. $500.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379048
Principal investigator 1 Daiichi Sankyo Inc. $4,340.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379050
Principal investigator 1 Daiichi Sankyo Inc. $500.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379052
Principal investigator 1 Daiichi Sankyo Inc. $500.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379054
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379056
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379058
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379060
Principal investigator 1 Daiichi Sankyo Inc. $4,340.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379062
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379068
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379074
Principal investigator 1 Daiichi Sankyo Inc. $2,709.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379076
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379112
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379114
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379116
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379120
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379122
Principal investigator 1 Daiichi Sankyo Inc. $2,709.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379124
Principal investigator 1 Daiichi Sankyo Inc. $3,229.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379126
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379128
Principal investigator 1 Daiichi Sankyo Inc. $2,709.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379130
Principal investigator 1 Daiichi Sankyo Inc. $3,229.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379134
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379136
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379140
Principal investigator 1 Daiichi Sankyo Inc. $2,709.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379142
Principal investigator 1 Daiichi Sankyo Inc. $3,229.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379144
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379146
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379292
Principal investigator 1 Daiichi Sankyo Inc. $4,703.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379296
Principal investigator 1 Daiichi Sankyo Inc. $4,703.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379322
Principal investigator 1 Daiichi Sankyo Inc. $3,760.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379332
Principal investigator 1 Daiichi Sankyo Inc. $5,040.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379338
Principal investigator 1 Daiichi Sankyo Inc. $3,229.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379342
Principal investigator 1 Daiichi Sankyo Inc. $2,709.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379344
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379362
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379376
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379406
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379408
Principal investigator 1 Incyte Corporation $2,000.00 05/14/2025 Non-covered Recipient Entity
FCS - CATTLEMEN
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma No dispute reported 06/30/2026 1240534026
Principal investigator 1 Incyte Corporation $2,000.00 05/12/2025 Non-covered Recipient Entity
FCS - CATTLEMEN
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma No dispute reported 06/30/2026 1240534022
Principal investigator 1 Incyte Corporation $43.00 05/12/2025 Non-covered Recipient Entity
FCS - CATTLEMEN
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma No dispute reported 06/30/2026 1240534029
Principal investigator 1 Incyte Corporation $43.00 05/12/2025 Non-covered Recipient Entity
FCS - CATTLEMEN
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma No dispute reported 06/30/2026 1240534033
Principal investigator 1 Incyte Corporation $43.00 05/12/2025 Non-covered Recipient Entity
FCS - CATTLEMEN
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma No dispute reported 06/30/2026 1240534037
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,690.00 05/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220816866
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378800
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378802
Principal investigator 1 Daiichi Sankyo Inc. $500.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378806
Principal investigator 1 Daiichi Sankyo Inc. $500.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378814
Principal investigator 1 Daiichi Sankyo Inc. $500.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378820
Principal investigator 1 Daiichi Sankyo Inc. $3,432.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378822
Principal investigator 1 Daiichi Sankyo Inc. $459.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378824
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378826
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378846
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378866
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378868
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378874
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378880
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378886
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378890
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378936
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378940
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378954
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378958
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378960
Principal investigator 1 Daiichi Sankyo Inc. $1,740.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378962
Principal investigator 1 Daiichi Sankyo Inc. $500.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378964
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378978
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378980
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378982
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378984
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378986
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378996
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223378998
Principal investigator 1 Daiichi Sankyo Inc. $500.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379000
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379004
Principal investigator 1 Daiichi Sankyo Inc. $1,740.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379006
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379008
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379010
Principal investigator 1 Daiichi Sankyo Inc. $500.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379012
Principal investigator 1 Daiichi Sankyo Inc. $500.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379014
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379038
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379064
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379066
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379070
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379072
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379078
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379080
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379082
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379084
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379086
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379088
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379090
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379092
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379094
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379096
Principal investigator 1 Daiichi Sankyo Inc. $2,709.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379098
Principal investigator 1 Daiichi Sankyo Inc. $143.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379100
Principal investigator 1 Daiichi Sankyo Inc. $140.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379102
Principal investigator 1 Daiichi Sankyo Inc. $235.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379104
Principal investigator 1 Daiichi Sankyo Inc. $750.60 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379106
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379108
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379110
Principal investigator 1 Daiichi Sankyo Inc. $432.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379118
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379132
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379138
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379148
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379150
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379154
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379156
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379158
Principal investigator 1 Daiichi Sankyo Inc. $500.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379160
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379162
Principal investigator 1 Daiichi Sankyo Inc. $500.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379164
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379166
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379168
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379170
Principal investigator 1 Daiichi Sankyo Inc. $3,229.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379172
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379180
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379198
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379200
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379202
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379204
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379206
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379208
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379210
Principal investigator 1 Daiichi Sankyo Inc. $1,042.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379212
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379214
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379216
Principal investigator 1 Daiichi Sankyo Inc. $2,709.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379218
Principal investigator 1 Daiichi Sankyo Inc. $3,229.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379220
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379222
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379224
Principal investigator 1 Daiichi Sankyo Inc. $605.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379226
Principal investigator 1 Daiichi Sankyo Inc. $664.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379228
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379232
Principal investigator 1 Daiichi Sankyo Inc. $1,740.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379236
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379238
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379240
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379242
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379244
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379246
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379248
Principal investigator 1 Daiichi Sankyo Inc. $2,709.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379250
Principal investigator 1 Daiichi Sankyo Inc. $3,229.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379252
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379256
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379258
Principal investigator 1 Daiichi Sankyo Inc. $2,709.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379262
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379264
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379266
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379268
Principal investigator 1 Daiichi Sankyo Inc. $500.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379270
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379272
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379274
Principal investigator 1 Daiichi Sankyo Inc. $500.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379276
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379278
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379280
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379282
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379284
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379286
Principal investigator 1 Daiichi Sankyo Inc. $2,585.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379288
Principal investigator 1 Daiichi Sankyo Inc. $3,229.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379298
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379300
Principal investigator 1 Daiichi Sankyo Inc. $500.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379302
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379304
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379306
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379308
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379310
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379312
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379314
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379324
Principal investigator 1 Daiichi Sankyo Inc. $5,040.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379328
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379330
Principal investigator 1 Daiichi Sankyo Inc. $2,843.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379334
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379340
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379346
Principal investigator 1 Daiichi Sankyo Inc. $500.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379352
Principal investigator 1 Daiichi Sankyo Inc. $500.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379354
Principal investigator 1 Daiichi Sankyo Inc. $5,040.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379358
Principal investigator 1 Daiichi Sankyo Inc. $2,709.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379360
Principal investigator 1 Daiichi Sankyo Inc. $1,731.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379366
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379370
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379372
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379374
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379378
Principal investigator 1 Daiichi Sankyo Inc. $3,229.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379380
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379382
Principal investigator 1 Daiichi Sankyo Inc. $5,040.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379392
Principal investigator 1 Daiichi Sankyo Inc. $4,703.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379394
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379396
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379398
Principal investigator 1 Daiichi Sankyo Inc. $2,709.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379400
Principal investigator 1 Daiichi Sankyo Inc. $2,149.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223379402
Principal investigator 1 Genentech, Inc. $172.48 05/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211651541
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,600.00 05/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220796945
Principal investigator 1 Blueprint Medicines Corporation $3,131.25 05/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1235784850
Principal investigator 1 Novartis Pharmaceuticals Corporation $38,743.53 05/07/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS
An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors No dispute reported 06/30/2026 1190305007
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,700.00 05/06/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220796943
Principal investigator 1 ABBVIE INC. $3,733.43 04/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480131
Principal investigator 1 ABBVIE INC. $2,126.25 04/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480141
Principal investigator 1 ABBVIE INC. $3,733.43 04/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480297
Principal investigator 1 ABBVIE INC. $1,791.45 04/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480299
Principal investigator 1 ABBVIE INC. $4,521.15 04/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480337
Principal investigator 1 ABBVIE INC. $2,030.40 04/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480339
Principal investigator 1 ABBVIE INC. $961.20 04/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480341
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $800.00 04/29/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220814629
Principal investigator 1 Janssen Research & Development, LLC $27,904.00 04/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175325391
Principal investigator 1 Genentech, Inc. $181.00 04/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211650902
Principal investigator 1 Genentech, Inc. $24,507.00 04/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211650905
Principal investigator 1 Genentech, Inc. $7,247.00 04/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211651060
Principal investigator 1 Genentech, Inc. $170.00 04/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211651123
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 04/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175322284
Principal investigator 1 ABBVIE INC. $2,333.00 04/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202478461
Principal investigator 1 Blueprint Medicines Corporation $2,500.00 04/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1235784875
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 04/23/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220640473
Principal investigator 1 Boehringer Ingelheim International GmbH $511.00 04/23/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220640475
Principal investigator 1 Boehringer Ingelheim International GmbH $4.80 04/23/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220640477
Principal investigator 1 Janssen Research & Development, LLC $610.40 04/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175319679
Principal investigator 1 Janssen Research & Development, LLC $450.00 04/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175322997
Principal investigator 1 Janssen Research & Development, LLC $6,500.00 04/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175325406
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 04/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175326488
Principal investigator 1 Daiichi Sankyo Inc. $913.00 04/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378105
Principal investigator 1 Daiichi Sankyo Inc. $3,413.00 04/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378107
Principal investigator 1 Daiichi Sankyo Inc. $3,413.00 04/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378109
Principal investigator 1 Daiichi Sankyo Inc. $3,413.00 04/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378111
Principal investigator 1 Daiichi Sankyo Inc. $1,299.00 04/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378183
Principal investigator 1 Daiichi Sankyo Inc. $6,732.00 04/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378189
Principal investigator 1 Genentech, Inc. $2,391.67 04/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211651528
Principal investigator 1 Genentech, Inc. $44.00 04/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211651597
Principal investigator 1 Genentech, Inc. $515.00 04/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph1 evaluating G6036 in pts with a KRAS Mutation No dispute reported 06/30/2026 1211651611
Principal investigator 1 ModernaTX, Inc. $4,000.00 04/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies No dispute reported 06/30/2026 1252969303
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $56.70 04/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220814627
Principal investigator 1 Blueprint Medicines Corporation $281.25 04/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1235784830
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,260.50 04/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220796941
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,200.00 04/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220814625
Principal investigator 1 SANOFI US SERVICES INC. $2,100.00 04/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies No dispute reported 06/30/2026 1226081998
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175319140
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175319423
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175319471
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175319744
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175320095
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175320864
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175321627
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175322074
Principal investigator 1 Janssen Research & Development, LLC $148.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175323762
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175323797
Principal investigator 1 Janssen Research & Development, LLC $2,555.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175324012
Principal investigator 1 Janssen Research & Development, LLC $2,555.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175324161
Principal investigator 1 Janssen Research & Development, LLC $2,555.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175324193
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175324417
Principal investigator 1 Janssen Research & Development, LLC $600.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175325217
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175326405
Principal investigator 1 ModernaTX, Inc. $790.00 04/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies No dispute reported 06/30/2026 1252969299
Principal investigator 1 ABBVIE INC. $2,333.00 04/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202468669
Principal investigator 1 Daiichi Sankyo Inc. $194.00 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378133
Principal investigator 1 Genentech, Inc. $66.00 04/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph1 evaluating G6036 in pts with a KRAS Mutation No dispute reported 06/30/2026 1211650880
Principal investigator 1 Genentech, Inc. $25.00 04/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph1 evaluating G6036 in pts with a KRAS Mutation No dispute reported 06/30/2026 1211650987
Principal investigator 1 Genentech, Inc. $66.00 04/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph1 evaluating G6036 in pts with a KRAS Mutation No dispute reported 06/30/2026 1211651002
Principal investigator 1 Genentech, Inc. $66.00 04/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph1 evaluating G6036 in pts with a KRAS Mutation No dispute reported 06/30/2026 1211651161
Principal investigator 1 Genentech, Inc. $25.00 04/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph1 evaluating G6036 in pts with a KRAS Mutation No dispute reported 06/30/2026 1211651172
Principal investigator 1 Genentech, Inc. $25.00 04/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph1 evaluating G6036 in pts with a KRAS Mutation No dispute reported 06/30/2026 1211651261
Principal investigator 1 Genentech, Inc. $66.00 04/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph1 evaluating G6036 in pts with a KRAS Mutation No dispute reported 06/30/2026 1211651367
Principal investigator 1 Genentech, Inc. $66.00 04/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph1 evaluating G6036 in pts with a KRAS Mutation No dispute reported 06/30/2026 1211651423
Principal investigator 1 Genentech, Inc. $25.00 04/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph1 evaluating G6036 in pts with a KRAS Mutation No dispute reported 06/30/2026 1211651555
Principal investigator 1 Genentech, Inc. $25.00 04/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph1 evaluating G6036 in pts with a KRAS Mutation No dispute reported 06/30/2026 1211651570
Principal investigator 1 Janssen Research & Development, LLC $134,992.00 04/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175319982
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,092.15 04/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220814623
Principal investigator 1 ModernaTX, Inc. $187.50 04/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies No dispute reported 06/30/2026 1252969295
Principal investigator 1 ModernaTX, Inc. $1,942.50 04/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies No dispute reported 06/30/2026 1252969301
Principal investigator 1 ABBVIE INC. $1,156.95 03/31/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467404
Principal investigator 1 ABBVIE INC. $1,156.95 03/31/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467408
Principal investigator 1 ABBVIE INC. $4,521.15 03/31/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467422
Principal investigator 1 ABBVIE INC. $2,715.53 03/31/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467425
Principal investigator 1 ABBVIE INC. $4,521.15 03/31/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467558
Principal investigator 1 ABBVIE INC. $2,226.15 03/31/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467562
Principal investigator 1 ABBVIE INC. $3,733.43 03/31/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467565
Principal investigator 1 ABBVIE INC. $2,226.15 03/31/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467569
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $750.00 03/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer No dispute reported 06/30/2026 1233739063
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $750.00 03/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer No dispute reported 06/30/2026 1233739065
Principal investigator 1 Janssen Research & Development, LLC $42,404.00 03/31/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175318935
Principal investigator 1 Novartis Pharmaceuticals Corporation $845.00 03/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma No dispute reported 06/30/2026 1190305011
Principal investigator 1 Daiichi Sankyo Inc. $4,608.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368439
Principal investigator 1 Daiichi Sankyo Inc. $10,227.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368447
Principal investigator 1 Daiichi Sankyo Inc. $4,608.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368449
Principal investigator 1 Daiichi Sankyo Inc. $1,761.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368451
Principal investigator 1 Daiichi Sankyo Inc. $232.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368453
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368465
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368467
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368469
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368471
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368473
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368475
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368477
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368479
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368481
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368483
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368485
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368487
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368489
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368491
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368493
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368495
Principal investigator 1 Daiichi Sankyo Inc. $526.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368497
Principal investigator 1 Daiichi Sankyo Inc. $17,814.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368499
Principal investigator 1 Daiichi Sankyo Inc. $21,610.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368501
Principal investigator 1 Daiichi Sankyo Inc. $1,530.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368503
Principal investigator 1 Daiichi Sankyo Inc. $36,612.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368505
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368523
Principal investigator 1 Daiichi Sankyo Inc. $4,608.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368525
Principal investigator 1 Daiichi Sankyo Inc. $4,608.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368527
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368529
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368531
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368533
Principal investigator 1 Daiichi Sankyo Inc. $6,848.00 03/28/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368539
Principal investigator 1 Blueprint Medicines Corporation $2,500.00 03/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1235784689
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,600.00 03/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220796935
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220796937
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $312.50 03/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220796939
Principal investigator 1 Genentech, Inc. $1,415.00 03/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph1 evaluating G6036 in pts with a KRAS Mutation No dispute reported 06/30/2026 1211650606
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $300.00 03/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220796901
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $650.00 03/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220816864
Principal investigator 1 Daiichi Sankyo Inc. $500.00 03/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378503
Principal investigator 1 Daiichi Sankyo Inc. $500.00 03/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378505
Principal investigator 1 Daiichi Sankyo Inc. $3,413.00 03/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378509
Principal investigator 1 Daiichi Sankyo Inc. $500.00 03/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378513
Principal investigator 1 Daiichi Sankyo Inc. $3,413.00 03/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378537
Principal investigator 1 Daiichi Sankyo Inc. $500.00 03/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378539
Principal investigator 1 Daiichi Sankyo Inc. $3,413.00 03/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378545
Principal investigator 1 Daiichi Sankyo Inc. $3,413.00 03/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378547
Principal investigator 1 Daiichi Sankyo Inc. $3,413.00 03/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378551
Principal investigator 1 Daiichi Sankyo Inc. $3,413.00 03/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378557
Principal investigator 1 Daiichi Sankyo Inc. $3,413.00 03/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378563
Principal investigator 1 Daiichi Sankyo Inc. $500.00 03/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378571
Principal investigator 1 Daiichi Sankyo Inc. $500.00 03/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378587
Principal investigator 1 Daiichi Sankyo Inc. $500.00 03/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378589
Principal investigator 1 Daiichi Sankyo Inc. $1,638.00 03/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378591
Principal investigator 1 Daiichi Sankyo Inc. $500.00 03/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378599
Principal investigator 1 Daiichi Sankyo Inc. $1,638.00 03/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378661
Principal investigator 1 Daiichi Sankyo Inc. $3,413.00 03/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378692
Principal investigator 1 Daiichi Sankyo Inc. $3,413.00 03/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378694
Principal investigator 1 Daiichi Sankyo Inc. $3,413.00 03/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378702
Principal investigator 1 Daiichi Sankyo Inc. $500.00 03/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378704
Principal investigator 1 Daiichi Sankyo Inc. $926.00 03/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378720
Principal investigator 1 PFIZER INC. $2,203.20 03/22/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228789623
Principal investigator 1 PFIZER INC. $3,750.00 03/22/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228795198
Principal investigator 1 Celgene Corporation $4,295.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute Llc
A Phase 1, Multicenter, Open-label, Dose Finding Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects with Relapsed and Refractory Multiple Myeloma No dispute reported 06/30/2026 1222306813
Principal investigator 1 Daiichi Sankyo Inc. $115.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381772
Principal investigator 1 Daiichi Sankyo Inc. $65.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381774
Principal investigator 1 Daiichi Sankyo Inc. $115.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381776
Principal investigator 1 Daiichi Sankyo Inc. $65.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381778
Principal investigator 1 Daiichi Sankyo Inc. $78.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381780
Principal investigator 1 Daiichi Sankyo Inc. $68.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381782
Principal investigator 1 Daiichi Sankyo Inc. $115.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381784
Principal investigator 1 Daiichi Sankyo Inc. $68.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381786
Principal investigator 1 Daiichi Sankyo Inc. $115.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381788
Principal investigator 1 Daiichi Sankyo Inc. $78.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381790
Principal investigator 1 Daiichi Sankyo Inc. $115.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381792
Principal investigator 1 Daiichi Sankyo Inc. $68.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381794
Principal investigator 1 Daiichi Sankyo Inc. $65.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381796
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381798
Principal investigator 1 Daiichi Sankyo Inc. $49.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381828
Principal investigator 1 Daiichi Sankyo Inc. $61.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381830
Principal investigator 1 Daiichi Sankyo Inc. $65.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381832
Principal investigator 1 Daiichi Sankyo Inc. $46.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381834
Principal investigator 1 Daiichi Sankyo Inc. $65.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381836
Principal investigator 1 Daiichi Sankyo Inc. $53.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381892
Principal investigator 1 Daiichi Sankyo Inc. $46.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381904
Principal investigator 1 Daiichi Sankyo Inc. $53.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381906
Principal investigator 1 Daiichi Sankyo Inc. $46.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381908
Principal investigator 1 Daiichi Sankyo Inc. $45.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381910
Principal investigator 1 Daiichi Sankyo Inc. $49.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381912
Principal investigator 1 Daiichi Sankyo Inc. $46.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381926
Principal investigator 1 Daiichi Sankyo Inc. $65.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381928
Principal investigator 1 Daiichi Sankyo Inc. $68.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381930
Principal investigator 1 Daiichi Sankyo Inc. $49.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381932
Principal investigator 1 Daiichi Sankyo Inc. $1,550.00 03/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381946
Principal investigator 1 Genentech, Inc. $181.00 03/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211650302
Principal investigator 1 Genentech, Inc. $2,410.00 03/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211650495
Principal investigator 1 Genentech, Inc. $2,410.00 03/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211650760
Principal investigator 1 Janssen Research & Development, LLC $375.00 03/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175320515
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 03/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175320564
Principal investigator 1 Janssen Research & Development, LLC $3,028.00 03/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175322483
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 03/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175322802
Principal investigator 1 Janssen Research & Development, LLC $500.00 03/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175325674
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 03/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175325927
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 03/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175326550
Principal investigator 1 Daiichi Sankyo Inc. $4,777.00 03/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378401
Principal investigator 1 Daiichi Sankyo Inc. $194.00 03/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378403
Principal investigator 1 Daiichi Sankyo Inc. $4,777.00 03/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378405
Principal investigator 1 Daiichi Sankyo Inc. $366.24 03/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378407
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 03/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378409
Principal investigator 1 Daiichi Sankyo Inc. $3,200.00 03/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378411
Principal investigator 1 Daiichi Sankyo Inc. $4,777.00 03/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378714
Principal investigator 1 Blueprint Medicines Corporation $281.25 03/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1235784660
Principal investigator 1 ModernaTX, Inc. $490.00 03/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies No dispute reported 06/30/2026 1252969297
Principal investigator 1 Genentech, Inc. $87,195.15 03/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph1 evaluating G6036 in pts with a KRAS Mutation No dispute reported 06/30/2026 1211650676
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 03/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378429
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,600.00 03/06/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220796933
Principal investigator 1 AstraZeneca UK Limited $690.00 03/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
";A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administratered Orally in Combination with Intramuscular (IM) Fulvestrant to patients with Estrogen Receptor Positive (ER+) Advanced Metastatic Breast Cancer"; No dispute reported 06/30/2026 1185538791
Principal investigator 1 Daiichi Sankyo Inc. $115.00 03/05/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378413
Principal investigator 1 Daiichi Sankyo Inc. $182.00 03/05/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378415
Principal investigator 1 Daiichi Sankyo Inc. $115.00 03/05/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378417
Principal investigator 1 Daiichi Sankyo Inc. $4,777.00 03/05/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378419
Principal investigator 1 Daiichi Sankyo Inc. $182.00 03/05/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378421
Principal investigator 1 Daiichi Sankyo Inc. $115.00 03/05/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378423
Principal investigator 1 Daiichi Sankyo Inc. $115.00 03/05/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378425
Principal investigator 1 Daiichi Sankyo Inc. $49.00 03/05/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378427
Principal investigator 1 Daiichi Sankyo Inc. $182.00 03/05/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378431
Principal investigator 1 Daiichi Sankyo Inc. $115.00 03/05/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378433
Principal investigator 1 Daiichi Sankyo Inc. $1,500.00 03/05/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378435
Principal investigator 1 Daiichi Sankyo Inc. $115.00 03/05/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378437
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 03/05/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378439
Principal investigator 1 Daiichi Sankyo Inc. $50.00 03/05/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378682
Principal investigator 1 Daiichi Sankyo Inc. $182.00 03/05/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378688
Principal investigator 1 Daiichi Sankyo Inc. $366.24 03/05/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378690
Principal investigator 1 PFIZER INC. $8,164.80 03/04/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228778761
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $625.00 03/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220796931
Principal investigator 1 Daiichi Sankyo Inc. $6.06 03/03/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368315
Principal investigator 1 Daiichi Sankyo Inc. $39.45 03/03/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368317
Principal investigator 1 Daiichi Sankyo Inc. $131.50 03/03/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368319
Principal investigator 1 Daiichi Sankyo Inc. $131.50 03/03/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368321
Principal investigator 1 Daiichi Sankyo Inc. $65.75 03/03/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368323
Principal investigator 1 Daiichi Sankyo Inc. $65.75 03/03/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368367
Principal investigator 1 Janssen Research & Development, LLC $42,729.00 03/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175319503
Principal investigator 1 ModernaTX, Inc. $1,000.00 03/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies No dispute reported 06/30/2026 1252969291
Principal investigator 1 ABBVIE INC. $3,370.95 02/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202455226
Principal investigator 1 ABBVIE INC. $3,370.95 02/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202455229
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $125.00 02/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220796929
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,131.00 02/27/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220796915
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,131.00 02/27/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220796917
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,131.00 02/27/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220796919
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,131.00 02/27/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220796921
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,131.00 02/27/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220796923
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,131.00 02/27/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220796925
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $156.25 02/27/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220796927
Principal investigator 1 PFIZER INC. $4,692.60 02/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228743050
Principal investigator 1 Daiichi Sankyo Inc. $45.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381708
Principal investigator 1 Daiichi Sankyo Inc. $46.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381710
Principal investigator 1 Daiichi Sankyo Inc. $61.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381712
Principal investigator 1 Daiichi Sankyo Inc. $46.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381714
Principal investigator 1 Daiichi Sankyo Inc. $46.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381716
Principal investigator 1 Daiichi Sankyo Inc. $65.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381718
Principal investigator 1 Daiichi Sankyo Inc. $61.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381720
Principal investigator 1 Daiichi Sankyo Inc. $68.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381722
Principal investigator 1 Daiichi Sankyo Inc. $68.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381724
Principal investigator 1 Daiichi Sankyo Inc. $46.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381726
Principal investigator 1 Daiichi Sankyo Inc. $46.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381728
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381730
Principal investigator 1 Daiichi Sankyo Inc. $115.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381732
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381734
Principal investigator 1 Daiichi Sankyo Inc. $115.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381736
Principal investigator 1 Daiichi Sankyo Inc. $115.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381738
Principal investigator 1 Daiichi Sankyo Inc. $115.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381740
Principal investigator 1 Daiichi Sankyo Inc. $115.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381742
Principal investigator 1 Daiichi Sankyo Inc. $115.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381744
Principal investigator 1 Daiichi Sankyo Inc. $115.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381746
Principal investigator 1 Daiichi Sankyo Inc. $366.24 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381748
Principal investigator 1 Daiichi Sankyo Inc. $115.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381750
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381752
Principal investigator 1 Daiichi Sankyo Inc. $2,132.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381754
Principal investigator 1 Daiichi Sankyo Inc. $3,675.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381756
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381758
Principal investigator 1 Daiichi Sankyo Inc. $2,132.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381760
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381762
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381764
Principal investigator 1 Daiichi Sankyo Inc. $115.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381766
Principal investigator 1 Daiichi Sankyo Inc. $2,132.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381768
Principal investigator 1 Daiichi Sankyo Inc. $157.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381770
Principal investigator 1 Daiichi Sankyo Inc. $115.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381924
Principal investigator 1 Daiichi Sankyo Inc. $78.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381934
Principal investigator 1 Daiichi Sankyo Inc. $115.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381940
Principal investigator 1 Daiichi Sankyo Inc. $2,132.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381942
Principal investigator 1 Daiichi Sankyo Inc. $46.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381948
Principal investigator 1 Daiichi Sankyo Inc. $46.00 02/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381950
Principal investigator 1 PFIZER INC. $4,200.00 02/22/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228754016
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,130.20 02/21/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220814621
Principal investigator 1 Incyte Corporation $2,000.00 02/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma No dispute reported 06/30/2026 1240586337
Principal investigator 1 ModernaTX, Inc. $190,000.00 02/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies No dispute reported 06/30/2026 1252969305
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,546.70 02/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220796913
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 02/19/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368425
Principal investigator 1 Daiichi Sankyo Inc. $36,612.00 02/19/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368427
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 02/19/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368429
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 02/19/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368431
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 02/19/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368433
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 02/19/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368435
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 02/19/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368437
Principal investigator 1 Daiichi Sankyo Inc. $1,530.00 02/19/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368441
Principal investigator 1 Daiichi Sankyo Inc. $4,608.00 02/19/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368443
Principal investigator 1 Daiichi Sankyo Inc. $4,608.00 02/19/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368445
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 02/19/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368455
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 02/19/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368457
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 02/19/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368459
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 02/19/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368461
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 02/19/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368463
Principal investigator 1 Daiichi Sankyo Inc. $8,805.00 02/19/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368507
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 02/19/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368509
Principal investigator 1 Daiichi Sankyo Inc. $17,814.00 02/19/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368511
Principal investigator 1 Daiichi Sankyo Inc. $526.00 02/19/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368513
Principal investigator 1 Daiichi Sankyo Inc. $12,966.00 02/19/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368515
Principal investigator 1 Daiichi Sankyo Inc. $1,160.00 02/19/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368517
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 02/19/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368519
Principal investigator 1 Daiichi Sankyo Inc. $6,848.00 02/19/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368521
Principal investigator 1 Daiichi Sankyo Inc. $10,227.00 02/19/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368535
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 02/19/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1471-079 No dispute reported 06/30/2026 1223368537
Principal investigator 1 ABBVIE INC. $2,333.00 02/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202452115
Principal investigator 1 Genentech, Inc. $53,380.00 02/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211650452
Principal investigator 1 Genentech, Inc. $2,410.00 02/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211650567
Principal investigator 1 Genentech, Inc. $2,427.00 02/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211650712
Principal investigator 1 Genentech, Inc. $2,410.00 02/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1211650859
Principal investigator 1 Janssen Research & Development, LLC $8,725.00 02/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175319495
Principal investigator 1 Janssen Research & Development, LLC $757.00 02/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175325712
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 02/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175326089
Principal investigator 1 Genentech, Inc. $2,536.00 02/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph1 evaluating G6036 in pts with a KRAS Mutation No dispute reported 06/30/2026 1211650318
Principal investigator 1 Genentech, Inc. $375.00 02/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Ph1 evaluating G6036 in pts with a KRAS Mutation No dispute reported 06/30/2026 1211650323
Principal investigator 1 Syndax Pharmaceuticals, Inc. $3,890.00 02/05/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS - SOUTH
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION COHORT STUDY OF SNDX-5613 IN PATIENTS WITH RELAPSED/REFRACTORY LEUKEMIAS, INCLUDING THOSE HARBORING AN MLL/KMT2A GENE REARRANGEMENT OR NUCLEOPHOSMIN 1 (NPM1) MUTATION No dispute reported 06/30/2026 1249050090
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368099
Principal investigator 1 Daiichi Sankyo Inc. $70.80 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368101
Principal investigator 1 Daiichi Sankyo Inc. $127.20 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368103
Principal investigator 1 Daiichi Sankyo Inc. $127.20 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368105
Principal investigator 1 Daiichi Sankyo Inc. $70.80 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368107
Principal investigator 1 Daiichi Sankyo Inc. $70.80 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368109
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368111
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368113
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368115
Principal investigator 1 Daiichi Sankyo Inc. $70.80 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368117
Principal investigator 1 Daiichi Sankyo Inc. $70.80 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368119
Principal investigator 1 Daiichi Sankyo Inc. $70.80 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368121
Principal investigator 1 Daiichi Sankyo Inc. $70.80 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368123
Principal investigator 1 Daiichi Sankyo Inc. $70.80 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368125
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368127
Principal investigator 1 Daiichi Sankyo Inc. $70.80 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368129
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368131
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368133
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368135
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368137
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368139
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368141
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368143
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368145
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368147
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368149
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368151
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368153
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368155
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368157
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368159
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368161
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368163
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368165
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368167
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368169
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368171
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368173
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368175
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368177
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368179
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368181
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368183
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368185
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368187
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368189
Principal investigator 1 Daiichi Sankyo Inc. $52.60 02/04/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS1103-074 No dispute reported 06/30/2026 1223368191
Principal investigator 1 Janssen Research & Development, LLC $113,942.00 02/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175324388
Principal investigator 1 Blueprint Medicines Corporation $2,500.00 02/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1235784684
Principal investigator 1 Janssen Research & Development, LLC $90,937.00 02/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175322261
Principal investigator 1 SANOFI US SERVICES INC. $490.00 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Inst Llc
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies No dispute reported 06/30/2026 1226084948
Principal investigator 1 SANOFI US SERVICES INC. $2,100.00 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institution Llc
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies No dispute reported 06/30/2026 1226147759
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 01/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220639432
Principal investigator 1 Eli Lilly and Company $94,489.25 01/31/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 1/2 STUDY OF ORAL LOXO-305 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR NON-HODGKIN LYMPHOMA (NHL) No dispute reported 06/30/2026 1187889316
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $750.00 01/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer No dispute reported 06/30/2026 1233739067
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,429.50 01/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS
A Phase I/Ib, Open-label, Multi-center, Study of QEQ278 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190305013
Principal investigator 1 ABBVIE INC. $2,333.00 01/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442195
Principal investigator 1 ABBVIE INC. $2,126.25 01/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202441403
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $300.00 01/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220816862
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $14,781.12 01/27/2025 Non-covered Recipient Entity
Florida Cancer Specialists (sarasota)
A Phase 1, Open-label Study of BMS-986460 in Participants with Metastatic Castration-resistant Prostate Cancer No dispute reported 06/30/2026 1235997319
Principal investigator 1 Eli Lilly and Company $1,605.19 01/27/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS
A PHASE 1/2 STUDY OF ORAL LOXO-305 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR NON-HODGKIN LYMPHOMA (NHL) No dispute reported 06/30/2026 1187881532
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,600.00 01/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220796911
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $800.00 01/24/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab No dispute reported 06/30/2026 1220814619
Principal investigator 1 PFIZER INC. $32,400.00 01/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228797841
Principal investigator 1 ABBVIE INC. $116.10 01/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202440748
Principal investigator 1 ABBVIE INC. $675.00 01/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202440751
Principal investigator 1 Blueprint Medicines Corporation $2,500.00 01/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1235784680
Principal investigator 1 Incyte Corporation $2,000.00 01/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma No dispute reported 06/30/2026 1240586327
Principal investigator 1 PFIZER INC. $6,600.00 01/22/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228798246
Principal investigator 1 Daiichi Sankyo Inc. $1,257.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378387
Principal investigator 1 Daiichi Sankyo Inc. $2,418.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378389
Principal investigator 1 Daiichi Sankyo Inc. $1,459.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378391
Principal investigator 1 Daiichi Sankyo Inc. $2,418.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378393
Principal investigator 1 Daiichi Sankyo Inc. $1,257.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378395
Principal investigator 1 Daiichi Sankyo Inc. $2,125.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378399
Principal investigator 1 Daiichi Sankyo Inc. $3,413.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378613
Principal investigator 1 Daiichi Sankyo Inc. $1,122.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378615
Principal investigator 1 Daiichi Sankyo Inc. $1,122.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378617
Principal investigator 1 Daiichi Sankyo Inc. $3,413.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378619
Principal investigator 1 Daiichi Sankyo Inc. $1,304.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378621
Principal investigator 1 Daiichi Sankyo Inc. $4,922.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378623
Principal investigator 1 Daiichi Sankyo Inc. $1,304.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378625
Principal investigator 1 Daiichi Sankyo Inc. $3,413.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378627
Principal investigator 1 Daiichi Sankyo Inc. $1,304.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378629
Principal investigator 1 Daiichi Sankyo Inc. $4,693.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS1103-074 No dispute reported 06/30/2026 1223378631
Principal investigator 1 Daiichi Sankyo Inc. $3,595.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381704
Principal investigator 1 Daiichi Sankyo Inc. $500.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381706
Principal investigator 1 Daiichi Sankyo Inc. $2,047.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381800
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381802
Principal investigator 1 Daiichi Sankyo Inc. $4,340.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381804
Principal investigator 1 Daiichi Sankyo Inc. $500.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381806
Principal investigator 1 Daiichi Sankyo Inc. $3,556.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381808
Principal investigator 1 Daiichi Sankyo Inc. $3,595.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381810
Principal investigator 1 Daiichi Sankyo Inc. $1,628.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381812
Principal investigator 1 Daiichi Sankyo Inc. $2,607.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381814
Principal investigator 1 Daiichi Sankyo Inc. $1,628.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381816
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381818
Principal investigator 1 Daiichi Sankyo Inc. $2,047.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381820
Principal investigator 1 Daiichi Sankyo Inc. $2,607.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381822
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381824
Principal investigator 1 Daiichi Sankyo Inc. $1,628.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381826
Principal investigator 1 Daiichi Sankyo Inc. $4,836.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381838
Principal investigator 1 Daiichi Sankyo Inc. $4,836.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381840
Principal investigator 1 Daiichi Sankyo Inc. $4,836.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381842
Principal investigator 1 Daiichi Sankyo Inc. $4,836.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381844
Principal investigator 1 Daiichi Sankyo Inc. $2,951.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381846
Principal investigator 1 Daiichi Sankyo Inc. $500.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381848
Principal investigator 1 Daiichi Sankyo Inc. $3,556.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381850
Principal investigator 1 Daiichi Sankyo Inc. $3,316.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381852
Principal investigator 1 Daiichi Sankyo Inc. $3,316.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381854
Principal investigator 1 Daiichi Sankyo Inc. $2,951.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381856
Principal investigator 1 Daiichi Sankyo Inc. $2,951.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381858
Principal investigator 1 Daiichi Sankyo Inc. $3,316.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381860
Principal investigator 1 Daiichi Sankyo Inc. $500.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381862
Principal investigator 1 Daiichi Sankyo Inc. $3,316.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381864
Principal investigator 1 Daiichi Sankyo Inc. $2,607.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381866
Principal investigator 1 Daiichi Sankyo Inc. $500.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381868
Principal investigator 1 Daiichi Sankyo Inc. $3,595.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381872
Principal investigator 1 Daiichi Sankyo Inc. $3,108.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381874
Principal investigator 1 Daiichi Sankyo Inc. $1,628.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381876
Principal investigator 1 Daiichi Sankyo Inc. $1,628.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381880
Principal investigator 1 Daiichi Sankyo Inc. $3,108.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381882
Principal investigator 1 Daiichi Sankyo Inc. $500.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381884
Principal investigator 1 Daiichi Sankyo Inc. $2,047.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381886
Principal investigator 1 Daiichi Sankyo Inc. $2,047.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381888
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381890
Principal investigator 1 Daiichi Sankyo Inc. $2,047.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381894
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381896
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381898
Principal investigator 1 Daiichi Sankyo Inc. $4,340.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381900
Principal investigator 1 Daiichi Sankyo Inc. $3,316.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381902
Principal investigator 1 Daiichi Sankyo Inc. $2,607.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381914
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381916
Principal investigator 1 Daiichi Sankyo Inc. $4,968.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381918
Principal investigator 1 Daiichi Sankyo Inc. $4,340.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381920
Principal investigator 1 Daiichi Sankyo Inc. $2,951.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381922
Principal investigator 1 Daiichi Sankyo Inc. $2,951.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381936
Principal investigator 1 Daiichi Sankyo Inc. $1,596.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381938
Principal investigator 1 Daiichi Sankyo Inc. $3,316.00 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS3939-077 No dispute reported 06/30/2026 1223381944
Principal investigator 1 ModernaTX, Inc. $1,630.00 01/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies No dispute reported 06/30/2026 1252969307
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,950.00 01/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma No dispute reported 06/30/2026 1190303755
Principal investigator 1 Novartis Pharmaceuticals Corporation $26,011.90 01/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase I/Ib, Open-label, Multi-center, Study of QEQ278 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190304475
Principal investigator 1 ABBVIE INC. $2,333.00 01/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202439667
Principal investigator 1 ABBVIE INC. $78.30 01/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202438897
Principal investigator 1 Blueprint Medicines Corporation $56.25 01/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1235784676
Principal investigator 1 Janssen Research & Development, LLC $4,974.00 01/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175322082
Principal investigator 1 Janssen Research & Development, LLC $4,600.00 01/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175323397
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 01/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175323595
Principal investigator 1 Janssen Research & Development, LLC $4,600.00 01/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1175324499
Principal investigator 1 Incyte Corporation $2,000.00 01/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUE AT HEALTHONE
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma No dispute reported 06/30/2026 1240586333
Principal investigator 1 SANOFI US SERVICES INC. $690.00 01/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Inst Llc
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies No dispute reported 06/30/2026 1226084952
Principal investigator 1 SANOFI US SERVICES INC. $2,100.00 01/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Inst Llc
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies No dispute reported 06/30/2026 1226084957
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,400.00 01/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination with Palbociclib in Women with ER Positive, HER2 Negative Advanced Breast Cancer No dispute reported 06/30/2026 1185538793
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,460.00 01/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220816860
Principal investigator 1 Celgene Corporation $102,221.08 01/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A phase 1, multi-center, open-label, dose finding study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cc-94676 in subjects with metastatic castration-resistant prostate cancer No dispute reported 06/30/2026 1222305502
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $114,248.50 01/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 1, Open-label Study of BMS-986460 in Participants with Metastatic Castration-resistant Prostate Cancer No dispute reported 06/30/2026 1235993975
Principal investigator 1 Janssen Research & Development, LLC $4,607.00 01/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175324471
Principal investigator 1 ModernaTX, Inc. $1,490.00 01/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies No dispute reported 06/30/2026 1252969293
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368259
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368261
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368263
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368265
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368267
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368269
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368271
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368273
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368275
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368277
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368279
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368281
Principal investigator 1 Daiichi Sankyo Inc. $78.90 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368283
Principal investigator 1 Daiichi Sankyo Inc. $78.90 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368285
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368287
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368289
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368291
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368293
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368295
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368297
Principal investigator 1 Daiichi Sankyo Inc. $16.16 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368299
Principal investigator 1 Daiichi Sankyo Inc. $105.20 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368301
Principal investigator 1 Daiichi Sankyo Inc. $132.80 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368303
Principal investigator 1 Daiichi Sankyo Inc. $105.20 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368305
Principal investigator 1 Daiichi Sankyo Inc. $105.20 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368307
Principal investigator 1 Daiichi Sankyo Inc. $12.12 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368309
Principal investigator 1 Daiichi Sankyo Inc. $468.70 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368311
Principal investigator 1 Daiichi Sankyo Inc. $132.80 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368313
Principal investigator 1 Daiichi Sankyo Inc. $70.80 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368325
Principal investigator 1 Daiichi Sankyo Inc. $70.80 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368327
Principal investigator 1 Daiichi Sankyo Inc. $14.36 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368329
Principal investigator 1 Daiichi Sankyo Inc. $70.80 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368331
Principal investigator 1 Daiichi Sankyo Inc. $70.80 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368333
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368335
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368337
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368339
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368341
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368343
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368345
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368347
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368349
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368351
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368353
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368355
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368357
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368359
Principal investigator 1 Daiichi Sankyo Inc. $135.30 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368361
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368363
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368365
Principal investigator 1 Daiichi Sankyo Inc. $4.76 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368369
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368371
Principal investigator 1 Daiichi Sankyo Inc. $52.60 01/02/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Sarasota Cattlemen
DS3939-077 No dispute reported 06/30/2026 1223368373
Principal investigator 1 Daiichi Sankyo Inc. $1.95 01/02/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377261
Principal investigator 1 Daiichi Sankyo Inc. $86.30 01/02/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377263
Principal investigator 1 Daiichi Sankyo Inc. $62.55 01/02/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377265
Principal investigator 1 Daiichi Sankyo Inc. $46.50 01/02/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377267
Principal investigator 1 Daiichi Sankyo Inc. $112.05 01/02/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377269
Principal investigator 1 Daiichi Sankyo Inc. $112.05 01/02/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377271
Principal investigator 1 Daiichi Sankyo Inc. $46.50 01/02/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377273
Principal investigator 1 Daiichi Sankyo Inc. $46.50 01/02/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377275
Principal investigator 1 Daiichi Sankyo Inc. $46.50 01/02/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377277
Principal investigator 1 Daiichi Sankyo Inc. $46.50 01/02/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377279
Principal investigator 1 Daiichi Sankyo Inc. $46.50 01/02/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377281
Principal investigator 1 Daiichi Sankyo Inc. $46.50 01/02/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377283
Principal investigator 1 Daiichi Sankyo Inc. $6.60 01/02/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377285
Principal investigator 1 Daiichi Sankyo Inc. $46.50 01/02/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377287
Principal investigator 1 Daiichi Sankyo Inc. $237.25 01/02/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377289
Principal investigator 1 Daiichi Sankyo Inc. $51.55 01/02/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377291
Principal investigator 1 Daiichi Sankyo Inc. $14.90 01/02/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377293
Principal investigator 1 Daiichi Sankyo Inc. $0.85 01/02/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377295
Principal investigator 1 Daiichi Sankyo Inc. $37.35 01/02/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377297
Principal investigator 1 Daiichi Sankyo Inc. $46.50 01/02/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377299
Principal investigator 1 Daiichi Sankyo Inc. $46.50 01/02/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377301
Principal investigator 1 Daiichi Sankyo Inc. $46.50 01/02/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377303
Principal investigator 1 Daiichi Sankyo Inc. $50.15 01/02/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377305
Principal investigator 1 Daiichi Sankyo Inc. $46.50 01/02/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377307
Principal investigator 1 Daiichi Sankyo Inc. $46.50 01/02/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377309
Principal investigator 1 Daiichi Sankyo Inc. $46.50 01/02/2025 Non-covered Recipient Entity
Regents Of The University Of Minnesota
DS7300-189 No dispute reported 06/30/2026 1223377311